The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Transplantation of an individual's own tissue from one site to another site.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
The transference of a part of or an entire liver from one human or animal to another.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Progenitor cells from which all blood cells derive.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
The transference of a kidney from one human or animal to another.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
The return of a sign, symptom, or disease after a remission.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An organism whose body contains cell populations of different genotypes as a result of the TRANSPLANTATION of donor cells after sufficient ionizing radiation to destroy the mature recipient's cells which would otherwise reject the donor cells.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Removal of bone marrow and evaluation of its histologic picture.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.
Elements of limited time intervals, contributing to particular results or situations.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
The transfer of leukocytes from a donor to a recipient or reinfusion to the donor.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The transference of a heart from one human or animal to another.
Disease having a short and relatively severe course.
Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).
An individual that contains cell populations derived from different zygotes.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The transference of either one or both of the lungs from one human or animal to another.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.
Disorders of the blood and blood forming tissues.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
A family composed of spouses and their children.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Transference of an organ between individuals of the same species or between individuals of different species.
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Immunological rejection of leukemia cells following bone marrow transplantation.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
Bone loss due to osteoclastic activity.
An encapsulated lymphatic organ through which venous blood filters.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A general term for various neoplastic diseases of the lymphoid tissue.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
The transference of a pancreas from one human or animal to another.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
Tumors or cancer located in bone tissue or specific BONES.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
Antibodies produced by a single clone of cells.
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.
The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Diseases of BONES.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Summarizing techniques used to describe the pattern of mortality and survival in populations. These methods can be applied to the study not only of death, but also of any defined endpoint such as the onset of disease or the occurrence of disease complications.
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Excessive formation of dense trabecular bone leading to pathological fractures; OSTEITIS; SPLENOMEGALY with infarct; ANEMIA; and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
The number of CELLS of a specific kind, usually measured per unit volume or area of sample.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
Irradiation of one half or both halves of the body in the treatment of disseminated cancer or widespread metastases. It is used to treat diffuse metastases in one session as opposed to multiple fields over an extended period. The more frequent treatment modalities are upper hemibody irradiation (UHBI) or lower hemibody irradiation (LHBI). Less common is mid-body irradiation (MBI). In the treatment of both halves of the body sequentially, hemibody irradiation permits radiotherapy of the whole body with larger doses of radiation than could be accomplished with WHOLE-BODY IRRADIATION. It is sometimes called "systemic" hemibody irradiation with reference to its use in widespread cancer or metastases. (P. Rubin et al. Cancer, Vol 55, p2210, 1985)
A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Proteins prepared by recombinant DNA technology.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Renewal or repair of lost bone tissue. It excludes BONY CALLUS formed after BONE FRACTURES but not yet replaced by hard bone.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
The immune responses of a host to a graft. A specific response is GRAFT REJECTION.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man,, August 20, 2004)
Group of disorders which feature accumulations of active HISTIOCYTES and LYMPHOCYTES, but where the histiocytes are not LANGERHANS CELLS. The group includes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; SINUS HISTIOCYTOSIS; xanthogranuloma; reticulohistiocytoma; JUVENILE XANTHOGRANULOMA; xanthoma disseminatum; as well as the lipid storage diseases (SEA-BLUE HISTIOCYTE SYNDROME; and NIEMANN-PICK DISEASES).
The induction of prolonged survival and growth of allografts of either tumors or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunized donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.
Transplantation between animals of different species.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Inflammation of the lung parenchyma that is caused by a viral infection.
Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
The grafting of bone from a donor site to a recipient site.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
Mice bearing mutant genes which are phenotypically expressed in the animals.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
The process of bone formation. Histogenesis of bone including ossification.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
The number of LYMPHOCYTES per unit volume of BLOOD.
Pathological processes of the OVARIES or the TESTES.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A decrease in the number of NEUTROPHILS found in the blood.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Pathological processes of the LIVER.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE) and characterized by progressive physical deterioration with urinary excretion of DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.
A subnormal level of BLOOD PLATELETS.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.

Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (1/8007)

Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle.  (+info)

Risk factors for severe hemorrhagic cystitis following BMT. (2/8007)

Hemorrhagic cystitis (HC) is a common toxicity of preparative regimens for bone marrow transplantation (BMT). Severe HC often requires prolonged and expensive hospitalization, and occasionally can result in death. To investigate the risk factors for severe HC, we conducted a retrospective study among 1908 patients who received BMTs at the University of Minnesota during 1974 to 1993. A previous report from our institution reported on 977 of these patients. We identified all patients with genitourinary complication within 100 days post-BMT from the BMT database. Medical charts for these patients were reviewed to determine whether the patient had HC and also the grade of HC. A total of 208 HC cases were identified during the study period. Of them, 92 patients had severe HC, an incidence of 5% (95% CI = 4-6%). We found that grade II-IV graft-versus-host disease (RR = 2.56; 95% CI = 1.43-4.56), use of busulfan (RR = 2.69; 95% CI = 1.35-5.35), and age at transplant (RR = 2.20; 95% CI = 1.27-3.81, for age of 10-30 compared to age of 0-9) were related to an increased risk of HC. In contrast, transplant year was inversely associated with the risk of HC (trend test, P < 0.01). We did not find any significant difference in HC with the use of prophylactic Mesna.  (+info)

Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. (3/8007)

Current guidelines for the treatment of catheter-related bacteraemia (CRB) advise against central venous catheter (CVC) exchange because of the potential risk of prolonging infection. However, there are no consistent data proving this recommendation. We evaluated prospectively the usefulness of CVC exchange by guidewire for the treatment of CRB in patients undergoing BMT or intensive chemotherapy. CVC exchange was considered when fever and positive blood cultures persisted after 2 days of adequate antimicrobial therapy and no potential source of bacteraemia other than CVC could be identified. The guidewire exchange was preceded and followed by a slow infusion of adequate antimicrobial therapy. Bacteraemia was confirmed as catheter-related by demonstrating concordance between isolates from the tip and blood cultures by pulsed-field electrophoresis of genomic DNA. This procedure was performed in 19 episodes of bacteraemia during a 1-year period. Fourteen episodes (74%) were catheter-related and 71% of these were due to coagulase-negative staphylococci. Guidewire replacement was accomplished uneventfully 4 days after development of sepsis (range 3-6). In all cases, clinical signs of sepsis disappeared in less than 24 h after replacement. Definitive catheter withdrawal was carried out a median of 16 days (range 3-42) after guidewire exchange; in all cases, the tip culture was negative. We conclude that CVC replacement by guidewire under adequate antimicrobial therapy may be a reasonable option for the treatment of CRB when antimicrobial therapy alone has been unsuccessful.  (+info)

The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. (4/8007)

At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchoscopy for CMV receive pre-emptive ganciclovir. In order to determine the utility of other screening methods for CMV, we prospectively performed weekly CMV antigenemia, and blood, urine and throat cultures from time of engraftment to day 120 post-BMT in 126 consecutive patients. Pre-emptive ganciclovir was given to 11/81 patients (13.6%) because of a positive surveillance bronchoscopy for CMV. Results of CMV blood, urine and throat cultures and the antigenemia assay done prior to or at the time of the surveillance bronchoscopy were analyzed for their ability to predict the bronchoscopy result. The antigenemia test had the highest positive and negative predictive values (72% and 96%, respectively). The ability of these tests to predict CMV disease was evaluated in the 70 patients with a negative surveillance bronchoscopy who did not receive pre-emptive ganciclovir. Of 19 cases of active CMV disease, CMV antigenemia was positive in 15 patients (79%) a mean of 34 days preceding symptoms. Blood cultures were positive in 14/19 patients (74%) a mean of 31 days before onset of disease. CMV antigenemia is useful for predicting the surveillance bronchoscopy result, and also predicts the development of CMV disease in the majority of patients missed by the surveillance bronchoscopy.  (+info)

Disappearance of lupus anticoagulant after allogeneic bone marrow transplantation. (5/8007)

Lupus anticoagulant antibodies have never been reported to disappear after either allogeneic or autologous bone marrow transplantation in humans. We report the first case of disappearance of lupus anticoagulant antibodies in a patient without systemic lupus erythematosus or clinical evidence of other autoimmune disorders, who received an allogeneic bone marrow transplant as treatment for chronic myeloid leukemia. Although marrow transplantation is not a recognized therapy for antiphospholipid syndrome, our observation should be considered another example of the capability of intensive chemo-radiotherapy followed by stem cell transplantation to ablate a pathologic marrow clone resulting in an autoimmune disorder and improve, or even cure, some severe autoimmune diseases.  (+info)

Rapid autologous marrow recovery and eradication of infectious mononucleosis despite severe immunosuppression following second transplantation for aplastic anemia. (6/8007)

A patient with aplastic anemia failed to respond to immunosuppressive therapy and first marrow transplantation (BMT). Recovery of autologous hematopoiesis was rapid following a second stem cell transplant with a non-myeloablative preparatory regimen. The autologous immune response to infectious mononucleosis (IM) 4 weeks post-transplant was normal despite recent and ongoing severe immunosuppression.  (+info)

Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal. (7/8007)

GVHD is one of the most frequent complications of BMT and recently nephrotic syndrome (NS) has been described as a manifestation of chronic GVHD. Here, we present an AA patient who developed NS 1 year after BMT when cyclosporine was stopped. Renal biopsy showed focal sclerosis associated with membranous deposits. He also had other clinical manifestations of chronic GVHD: sicca-like syndrome and colestasis. After 15 days of CsA therapy, he experienced a remarkable improvement in the NS and GVHD as a whole. We comment on immunological mechanisms that could be involved in the pathogenesis of this manifestation.  (+info)

Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. (8/8007)

Conjugation of gonadotropin-releasing hormone (GnRH) analogues GnRH-III, MI-1544, and MI-1892 through lysyl side chains and a tetrapeptide spacer, Gly-Phe-Leu-Gly (X) to a copolymer, poly(N-vinylpyrrolidone-co-maleic acid) (P) caused increased antiproliferative activity toward MCF-7 and MDA-MB-231 breast, PC3 and LNCaP prostate, and Ishikawa endometrial cancer cell lines in culture and against tumor development by xenografts of the breast cancer cells in immunodeficient mice. MCF-7 cells treated with P-X-1544 and P-X-1892 displayed characteristic signs of apoptosis, including vacuoles in the cytoplasm, rounding up, apoptotic bodies, bleb formation, and DNA fragmentation. Conjugates, but not free peptides, inhibited cdc25 phosphatase and caused accumulation of Ishikawa and PC3 cells in the G2/M phase of the cell cycle after 24 h at lower doses and in the G1 and G2 phases after 48 h. Since P-X-peptides appear to be internalized, the increased cytotoxicity of the conjugates is attributed to protection of peptides from proteolysis, enhanced interaction of the peptides with the GnRH receptors, and/or internalization of P-X-peptide receptor complexes so that P can exert toxic effects inside, possibly by inhibiting enzymes involved in the cell cycle. The additional specificity of P-X-peptides compared with free peptides for direct antiproliferative effects on the cancer cells but not for interactions in the pituitary indicates the therapeutic potential of the conjugates.  (+info)

TY - JOUR. T1 - Successful bone marrow transplantation in a child with X-linked hyper-IgM syndrome. AU - Kato, T.. AU - Tsuge, I.. AU - Inaba, J.. AU - Kato, K.. AU - Matsuyama, T.. AU - Kojima, S.. PY - 1999. Y1 - 1999. N2 - We report a case of an 11-year-old boy who underwent successful bone marrow transplantation for X-linked hyper-IgM syndrome (XHIM). The donor was an HLA-matched brother. The patient was conditioned with busulfan, cyclophosphamide and anti-thymocyte globulin. He received 4.7 x 108 marrow cells per kg from the donor. Prophylaxis against graft-versus-host disease consisted of cyclosporine and short-term methotrexate. The clinical course after the bone marrow transplantation was uneventful, and 12 months after transplantation the patient was doing well with no need for therapy. We examined expression of the CD40 ligand (CD40L) on the patients activated T lymphocytes and in vitro production of immunoglobulins by his lymphocytes. Although expression of CD40L was totally absent ...
TY - JOUR. T1 - Recovery of erythropoiesis following allogeneic bone marrow transplantation for chronic lymphocytic leukaemia-associated pure red cell aplasia. AU - De Vetten, M. P.. AU - Van Gelder, M.. AU - De Greef, G. E.. PY - 2001. Y1 - 2001. N2 - Pure red cell aplasia is a rare condition, that can be either idiopathic or associated with a lymphoproliferative disorder. The latter is considered to result from T cell-mediated suppression of haematopoiesis, and usually responds well to treatment with immunosuppressive medication. We describe a patient with B-CLL-associated pure red cell aplasia who did not respond to several courses of immunosuppressive treatment. Erythropoiesis was finally restored after allogeneic bone marrow transplantation.. AB - Pure red cell aplasia is a rare condition, that can be either idiopathic or associated with a lymphoproliferative disorder. The latter is considered to result from T cell-mediated suppression of haematopoiesis, and usually responds well to ...
TY - JOUR. T1 - Epstein-barr-virus-related malignant b cell lymphoplasmacytic lymphoma following allogeneic bone marrow transplantation for aplastic anemia. AU - Forman, Stephen J.. AU - Sullivan, John L.. AU - Wright, Christine. AU - Ratech, Howard. AU - Racklin, Barbara. AU - Blume, Karl G.. PY - 1987. Y1 - 1987. N2 - The development of B cell lymphoma has been reported to occur in recipients of a variety of organ transplants, including some patients who have received an allogeneic bone marrow graft. In this report, we describe a patient with severe aplastic anemia who developed a malignant B cell lymphoplasmacytoid proliferation 48 days after undergoing allogeneic marrow transplantation from her HLA-matched MLC-nonreactive brother. Immunologic studies showed this malignancy to be a mixed polyclonal and monoclonal proliferation in donor ceils. Virologie studies documented Epstein Bare infection of the cells. A review of the literature suggests that graft-versus-host disease and treatment of ...
View the Pediatric Bone Marrow Transplantation Program statistics for St. Louis Childrens Hospital including number of procedures, statistics for both autologous and allogeneic patients and survivor ratings. For more information on the Pediatric Bone Marrow Transplant Program, call 314-454-KIDS (5437).
TY - JOUR. T1 - Lymphoproliferative disorders following allogeneic bone marrow transplantation. T2 - The Vancouver experience. AU - Micallef, I. N.M.. AU - Chhanabhai, M.. AU - Gascoyne, R. D.. AU - Shepherd, J. D.. AU - Fung, H. C.. AU - Nantel, S. H.. AU - Toze, C. L.. AU - Klingemann, H. G.. AU - Sutherland, H. J.. AU - Hogge, D. E.. AU - Nevill, T. J.. AU - Le, A.. AU - Barnett, M. J.. N1 - Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 1998. Y1 - 1998. N2 - Between June 1988 and May 1996, 428 patients underwent allogeneic BMT (288 related donor (RD) and 140 unrelated donor (UD)) at the Vancouver General Hospital. Eight patients (UD six and RD two) developed a post-transplant lymphoproliferative disorder (PTLD). Median age at BMT was 38 years (range 22-51). Five of the six UD allografts were T cell depleted. Cyclosporine ± methotrexate was used for GVHD prophylaxis, All eight patients developed GVHD; in six this was refractory to treatment with corticosteroids. Rabbit ...
TY - JOUR. T1 - Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. AU - Oh, H.. AU - Gale, R. P.. AU - Zhang, M. J.. AU - Passweg, J. R.. AU - Ino, T.. AU - Murakami, H.. AU - Ohno, R.. AU - Rowlings, P. A.. AU - Sobocinski, K. A.. AU - Tanimoto, M.. AU - Tomonaga, M.. AU - Weisdorf, D. J.. AU - Horowitz, M. M.. PY - 1998. Y1 - 1998. N2 - There is controversy about whether chemotherapy or an HLA-identical sibling bone marrow transplant is better treatment for adults with acute lymphoblastic leukemia (ALL) in first remission. A previous study of patients treated in 1980-1987 showed similar leukemia-free survivals with these approaches. We re-examined this issue in more recently treated patients receiving different chemotherapy. Chemotherapy subjects (n = 76) participated in trial ALL-87 of the Japan Adult Leukemia Study Group (JALSG). Transplant subjects (n = 214) were reported to the International Bone Marrow Transplant ...
Searching for the cost of Autologous Bone Marrow Transplant in Faridabad? Contact Lyfboat to Get an Expert Second Opinion & Personalised Quote for Autologous Bone Marrow Transplant from the best Autologous Bone Marrow Transplant hospitals in Faridabad. We enable patients to connect, communicate and find quality healthcare for Autologous Bone Marrow Transplant in Faridabad.
An advanced pediatric bone marrow transplant is available through the International Medicine Department at Sheba Medical Center in Israel. Learn more now.
Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Hauke, R.J.; Greiner, T.C.; Smir, B.N.; Vose, J.M.; Tarantolo, S.R.; Bashir, R.M.; Bierman, P.J. // Bone Marrow Transplantation;6/15/98, Vol. 21 Issue 12, p1271 Epstein-Barr virus-associated lymphoproliferative disorders have been frequently reported as a complication of solid organ and allogeneic bone marrow transplantation. Their occurrence is rare after autologous bone marrow transplantation (BMT) with only five published reports in the literature.... ...
TY - JOUR. T1 - Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. AU - Anderson, Larry D.. AU - Savary, Cherylyn A.. AU - Mullen, Craig A.. PY - 2000/4/1. Y1 - 2000/4/1. N2 - Allogeneic bone marrow transplantation (BMT) induces 2 closely associated immune responses: graft-versus-tumor (GVT) activity and graft- versus-host disease (GVHD). We have previously shown that pretransplant immunization of allogeneic BMT donors with a recipient-derived tumor cell vaccine increases both GVT activity and lethal GVHD because of the priming of donor T cells against putative minor histocompatibility antigens (mHAgs) on the tumor vaccine cells. The work reported here tested the hypothesis that tumor cell vaccination after BMT would produce an increase in GVT activity without exacerbating GVHD. C3H.SW donor bone marrow and splenocytes were transplanted into major histocompatibility ...
TY - JOUR. T1 - Bone marrow engraftment and GVHD following bone marrow transplantation across a concordant xenogeneic barrier (mouse to rat). AU - Li, H.. AU - Selvaggi, G.. AU - Ricordi, C.. AU - Inverardi, L.. PY - 1997/7/7. Y1 - 1997/7/7. UR - UR - U2 - 10.1016/S0041-1345(97)00288-1. DO - 10.1016/S0041-1345(97)00288-1. M3 - Article. C2 - 9193584. AN - SCOPUS:0030979295. VL - 29. SP - 2190. EP - 2191. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 4. ER - ...
TY - JOUR. T1 - Prospective study of endocrine side-effects following bone marrow transplantation in childhood. AU - Bozzola, M.. AU - Locatelli, F.. AU - Cisternino, M.. AU - Bonetti, F.. AU - Gambarana, D.. AU - Giorgiani Zecca, G. M.. AU - De Stefano, P.. AU - Lorini, R.. AU - Severi, F.. PY - 1991. Y1 - 1991. N2 - An increasing number of children with various hematologic malignancies become long-term survivors following treatment with high dose chemotherapy, total body irradiation (TBI) and bone marrow transplantation (BMT). The doses of chemotherapy and irradiation used in transplant preparative regimens may affect endocrine function. Radiation may directly impair hypothalamic, pituitary, thyroid and gonadal function in a dose-dependent manner. Prospective study is needed to evaluate the long-term endocrine side effects of BMT.. AB - An increasing number of children with various hematologic malignancies become long-term survivors following treatment with high dose chemotherapy, total body ...
Goals: A retrospective study of pretransplantation risk factors predisposing to liver injury following bone marrow transplantation (BMT). Background: Liver complications are a major cause of morbidity and mortality following BMT. Determination of the pretransplantation factors that are likely to lead to liver injury may allow earlier diagnosis after BMT and may possibly improve prognosis. Study: Medical records of BMT patients were reviewed, and results of serial liver function tests and HBV/HCV serology during the pre- and posttransplantation 1-year period were noted. Presence of liver injury was defined as alanine aminotransferase levels twice the upper limit of normal. Forty-four allogeneic and 17 autologous BMTs, performed between 1990 and 2000, were analyzed in the study. Results and Conclusion: One-year survival was 77% (34 of 44 patients) for allogeneic BMT and 52% (9 of 17 patients) for autologous BMT. Seventy-two percent (32 of 44) of allogeneic transplant recipients and 47% (8 of 17) ...
TY - JOUR. T1 - Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation. AU - Champlin, R.. AU - Gajewski, J.. AU - Feig, S.. AU - Giorgi, J.. AU - Lyddane, N.. AU - Lee, K.. AU - Schmidt, I.. AU - Winston, D.. AU - Ho, W.. AU - Reichert, T.. N1 - Copyright: Copyright 2004 Elsevier B.V., All rights reserved.. PY - 1989. Y1 - 1989. UR - UR - M3 - Article. C2 - 2495694. AN - SCOPUS:0024602334. VL - 21. SP - 2947. EP - 2948. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 1 III. ER - ...
Polymerase chain reaction (PCR) is a very potent method enabling the amplification of target DNA sequences at least 10(5)-10(6) fold. The efficacy of PCR is measured by its specificity, efficiency (yield quantity) and fidelity. On the basis of PCR specificity, it is possible to differentiate host genom from virus or bacterial genom if they are in the host bloodstream. It is possible to make a precise diagnosis of an infectious disease. The result of bone marrow transplantation can also be more quickly predicted than by other techniques. Prognosis of engraftment following an allogeneic bone marrow transplantation was obtained by PCR amplification of the hypervariable region (HVR) lying on the 3end of the apolipoprotein B gene. This HVR polymorphism of the largest human gene (apoB) is very informative, considering that 16 alleles are registered in the Belgrade population. It is necessary to detect the HVR genotype of donor and host before and after allogenic bone marrow transplantation. ...The aim ...
TY - JOUR. T1 - Hepatitis C virus (HCV) infection in bone marrow transplant patients after transfusions from anti-HCV-positive blood donors. AU - Shuhart, M. C.. AU - Myerson, D.. AU - Spurgeon, C. L.. AU - Bevan, C. A.. AU - Sayers, M. H.. AU - McDonald, G. B.. PY - 1996/4/1. Y1 - 1996/4/1. N2 - In March 1992, 12 bone marrow transplant patients at the Fred Hutchinson Cancer Research Center received blood components from donors who were anti-HCV-nonreactive by first generation ELISA but whose serum later tested anti-HCV-reactive to a second generation ELISA. All these blood components were further tested for anti-HCV using a second-generation RIBA and for HCV RNA by polymerase chain reaction. Recipient sera were tested for HCV RNA prior to and following blood component infusion. Blood components from four donors were positive for HCV RNA. All recipients of HCV RNA-positive blood components became viremic on the first day tested post-infusion. In addition, two recipients of HCV RNA-negative blood ...
TY - JOUR. T1 - Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. AU - Frassoni, Francesco. AU - Labopin, Myriam. AU - Powles, Ray. AU - Mary, Jean Yves. AU - Arcese, William. AU - Bacigalupo, Andrea. AU - Bunjes, Donald. AU - Gluckman, Eliane. AU - Ruutu, Tapani. AU - Schaefer, Ulrich W.. AU - Sierra, Jorge. AU - Vernant, Jean Paul. AU - Willemze, Roel. AU - De Witte, Theo. AU - Gorin, Norbert Claude. PY - 2000/4/22. Y1 - 2000/4/22. N2 - Background: There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. Methods: We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors ...
Gonadal function after allogenic bone marrow transplantation for thalassaemia. Social integration of the older thalassaemic patient
We discuss clinical strategies for the prophylaxis and treatment of both acute and chronic graft-versus-host disease (GVHD) with particular attention to children. Grades II to IV acute GVHD occur in 10 to 50% of patients given an allogeneic transplantation of haemopoietic stem cells (HSCT) from a genotypically HLA-identical donor. A significantly higher incidence and severity of the disease is reported in patients receiving transplants from partially matched family donors or unrelated volunteers. Younger individuals or patients receiving HSCT from younger donors develop GVHD less frequently than do older recipients. Severe acute GVHD is characterised by a significant decrease in survival probability, even though the graft-versus-leukaemia activity associated with both acute and chronic GVHD may reduce the risk of leukaemia relapse. Prophylaxis of acute GVHD usually consists of in vivo post-grafting immunosuppression with cyclosporin alone or in combination with methotrexate; methotrexate alone ...
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patients immune system from rejecting the donors stem cells. When certain stem cells from a donor are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the bodys normal cells. Removing the T cells from the donor cells before transplant may stop this from happening.. PURPOSE: This randomized phase III trial is studying donor bone marrow that is treated in the laboratory using two different devices to compare how well they work in treating patients who are undergoing a donor bone marrow transplant for hematologic cancer. ...
Intensive, myelosuppressive therapy is necessary to maximize outcomes for patients with acute myeloid leukemia (AML). A comparison was made of 3 aggressive postremission approaches for children and adolescents with AML in a randomized trial, CCG-2891. A total of 652 children and adolescents with AML who achieved remission on 2 induction regimens using identical drugs and doses (standard and intensive timing) were eligible for allocation to allogeneic bone marrow transplantation (BMT) based on matched related donor status (n = 181) or randomization to autologous BMT (n = 177) or to aggressive high-dose cytarabine-based chemotherapy (n = 179). Only 115 patients (18%) refused to participate in the postremission phase of this study. Overall compliance with the 3 allocated regimens was 90%. At 8 years actuarial, 54% +/- 4% (95% confidence interval) of all remission patients remain alive. Survival by assigned regimen (intent to treat) is as follows: allogeneic BMT, 60% +/- 9%; autologous BMT, 48% ...
TY - JOUR. T1 - Autologous bone marrow transplantation for patients with advanced chronic myelogenous leukemia. AU - Nagamura-Inoue, Tokiko. AU - Tojo, Arinobu. AU - Ikebuchi, Kenji. AU - Takahashi, Satoshi. AU - Ogura, Hiromi. AU - Shindoh, Eiichi. AU - Nagamura, Fumitaka. AU - Uemura, Naoki. AU - Watari, Kiyoshi. AU - Irie, Seiji. AU - Setoyama, Misao. AU - Tajika, Kenji. AU - Nakayama, Michihiro. AU - Nagayama, Hitomi. AU - Kobayashi, Yukio. AU - Shirafuji, Naoki. AU - Sato, Noriharu. AU - Okamoto, Shin ichiro. AU - Ozawa, Keiya. AU - Tani, Kenzaburo. AU - Asano, Shigetaka. PY - 1997/12. Y1 - 1997/12. N2 - We report on seven chronic myelogenous leukemia (CML) patients who received autologous bone marrow transplantation (ABMT) using bone marrow (BM) cells while at the chronic phase (CP) under the various treatments. Of the seven patients, four progressed to accelerated phase (AP) in 83-248 weeks after onset and three patients entered blastic crisis (BC) in 84-171 weeks after onset. All ...
different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. Addition of a seconds profile, publications, research topics, and co-authors
We offer bone marrow, peripheral blood stem cell, and cord blood transplants for a wide range of diseases, including cancer, blood disorders, immune system diseases, genetic diseases, and bone marrow failure syndromes.Our highly trained medical team understands the application of research-based therapies, and cares for the unique needs of children undergoing bone marrow transplantation. In addition to physicians and nurse practitioners, our team includes a transplant coordinator, social worker, care coordinator, nutritionist, pharmacist, child life specialist, radiation oncologists, psychiatrist, and physical therapist.
BackgroundPneumonia carries significant morbidity and mortality in leukemic and bone marrow transplant patient. The development of pulmonary infiltrates in the setting of such immunocompromise raises concern for both infectious and non-infectious etiologies, some of which are potentially treatabl. Performing bronchoscopy provides several different options for sampling the lower respiratory tract. Among these, bronchoalveolar lavage (BAL) is especially effective at collecting samples from the alveoli and has been shown to be associated with less risk than transbonchial biops. We sought to examine the effect of antimicrobial treatment on BAL results in a large study population of leukemic and bone marrow transplant patients.Subjects and MethodsThis retrospective chart review was performed at a single academic cancer center. A power analysis was performed to determine the appropriate sample size. The patients were selected from those who had undergone an inpatient bronchoscopy in reverse chronological
TY - JOUR. T1 - A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. AU - Adkins, Douglas R.. AU - Irvin, Rebecca. AU - Kuhn, John. AU - Boldt, David H.. AU - Roodman, G. David. AU - Salzman, Donna. AU - Freytes, Cesar. AU - Von Hoff, D. D.. AU - LeMaistre, C. F.. PY - 1993/6. Y1 - 1993/6. N2 - Dacarbazine (DTIC) is a chemotherapy drug which has antitumor activity at standard doses, exhibits a steep dose-response effect in vitro, and is associated with relatively few non-hematologic toxicities. These characteristics suggest a potential role for this drug in bone marrow transplant preparative regimens. To pursue this hypothesis, 16 patients with refractory solid tumors were enrolled in a phase I study of single agent DTIC to determine the dose of DTIC requiring bone marrow reinfusion and to define the dose-limiting toxicity and maximum tolerated dose when given with autologous bone marrow rescue. Pharmacokinetics ...
TY - JOUR. T1 - Pulmonary embolism with bone fragments following vertebral body marrow infusion for tolerance induction. AU - Fernandez, Luis A.. AU - Romaguera, Rita. AU - Viciana, Ana L.. AU - Ruiz, Phillip. AU - Tzakis, Andreas G.. AU - Ricordi, Camillo. PY - 1996. Y1 - 1996. N2 - Protocols of donor bone marrow infusion for tolerance induction are receiving increasing attention in clinical trials of organ allotransplantation. We report pulmonary embolism with bone fragments following vertebral body marrow infusion in a recipient of a liver and intestinal transplant. Even though pulmonary embolism with bony microfragments has been widely described following bone marrow transplantation, the use of single, high-dose donor bone marrow infusion and/or multiple infusions currently under clinical investigation for induction of donor specific unresponsiveness, may warrant the implementation of additional steps in the vertebral body marrow processing technique to decrease or eliminate the component of ...
Invasive mold infections (IMIs) are an important cause of morbidity and mortality in patients who are undergoing bone marrow transplantation (BMT). To examine the epidemiology, risk factors, and outcome of IMIs in allogeneic BMT recipients, all cases of mold infection among 94 adult patients who underwent allogeneic BMT at this institution from 1 January 1997 through 31 December 1998 were reviewed retrospectively. Fifteen cases of IMI were identified; infection occurred a median of 102 days after BMT. Aspergillus species was the most common cause of disease, and species other than Aspergillus fumigatus were present in 53% of patients. By multivariate analysis, the variable associated with infection risk was systemic glucocorticosteroid use. Prophylactic antifungal therapy that was targeted to high-risk patients had little effect on disease incidence. These observations suggest that early identification of high-risk patients and better approaches to prevention should be explored, to reduce ...
Competitive bone marrow transplantation assay measures multi-lineage reconstitution of hematopoiesis in irradiated transplant recipient mice. Thus this assay is routinely used to determine haematopoietic stem and progenitor cells (HSPCs) functionality in vivo. The principle of the method is to transplant bone marrow donor cells (derived from transgenic mice of choice) on C57BL6 background together with normal competitor bone marrow. In order to distinguish donor from competitor cells upon transplantation, usually competitor mice are congenic and carry the differential B cell antigen originally designated Ly5.1 and CD45.1.A typical competitive bone marrow transplantation experiment will contain two transplantation groups, donor (transgenic mice of choice and their controls) are transplanted in competition with normal competitors and engraftment efficiency is evaluated in both blood and bone marrow.
TY - JOUR. T1 - Blood and bone marrow transplantation for acute myeloid leukemia. AU - Villela, Luis M.. AU - Bolanos Meade, F Javier. PY - 2009. Y1 - 2009. N2 - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission or those with poor-risk cytogenetics will benefit the most from this approach. With current transplantation techniques, outcomes have improved over recent years. Although relapse and graft-versus-host disease still are important problems faced by these patients, novel approaches have been developed to decrease the risk of complications, with excellent results.. AB - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission ...
A healthy immune system produces T cells that can recognize and react against foreign molecules (antigens) to protect against infection, while leaving normal host cells with self antigens undamaged. All T cells are produced in the thymus from blood stem cells that originate in the bone marrow and migrate through the blood circulation to the thymus. During aging, the thymus shrinks in size (involutes) and T cell production is limited, causing a poorly functioning immune system. T cell production and immune recovery is also slow and incomplete after bone marrow transplantation in older patients. In previous studies we showed that the thymus grows rapidly and T production is very robust in new-born mice. We also showed that during the new-born period, a growth factor called Vascular Endothelial Growth Factor (VEGF) is made at high levels in the thymus. When VEGF is inhibited in new-borns, T cell production falls, suggesting that this molecule plays an important role in thymic growth during this ...
And after more than 50 years of tireless investigations, this procedure has become standard treatment of hematologic malignancies. Despite major advances, bone marrow transplantation is still a difficult and evolving field. A newly published clinical resource called Clinical Manual of Blood and Bone Marrow Transplantation is a valuable addition to the literature on transplantation. Well-Organized Format EDITED BY Drs. Syed A. Abutalib and Parameswaran Hari, the book provides a concise practical expert review in a well-organized format of 42 chapters, each annotated with numerous practical headings to enhance focused learning. Stem cell transplantation is highly specialized, and this book is targeted for teachers and clinicians in the field. Each of the 42 chapters focuses on a particular topic and provides numerous reference tables and figures. The structure provides a neat and handy compendium for daily work caring for bone marrow transplant patients. It also offers a complete set of ...
OBJECTIVES: I. Compare the disease free survival of patients with leukemia, myelodysplasia, or lymphoblastic lymphoma after treatment with conventional (non-T cell depleted) or T cell depleted unrelated donor bone marrow transplantation. II. Compare the incidence of primary and secondary graft failure, acute and chronic graft-vs-host disease, complications (infection, veno-occlusive disease, interstitial pneumonitis), and relapse in these patients after these treatments. III. Compare the incidence of other malignancies, lymphoproliferative disorders, and post-transplant myelodysplasia in these patients after these treatments.. OUTLINE: This is a randomized, multicenter study. Patients will be stratified according to institution. Patients are assigned to one of two treatment arms, one with conventional bone marrow transplantation (arm I) and one with T cell depletion of the bone marrow (arm II). Arm I: Patients receive cyclophosphamide on days -6 and -5. Total body irradiation (TBI) is ...
TY - JOUR. T1 - Leukocyte low density lipoprotein receptor (LDL-R) does not contribute to LDL clearance in vivo. T2 - Bone marrow transplantation studies in the mouse. AU - Fazio, Sergio. AU - Hasty, Alyssa H.. AU - Carter, Kathy J.. AU - Murray, Alisa B.. AU - Price, James O.. AU - Linton, MacRae R.F.. PY - 1997/2/1. Y1 - 1997/2/1. N2 - The targeted disruption of the low density lipoprotein (LDL) receptor gene in mice results in accumulation of plasma LDL cholesterol and in predisposition to diet-induced aortic atherosclerosis. Although the liver is the central organ for receptor mediated clearance of LDL, the in vivo role of other organs and tissues in LDL catabolism has not been directly studied. Since bone marrow-derived cells such as blood leukocytes and tissue macrophages express LDL receptors and contribute a large cell mass to the body, we designed bone marrow transplantation (BMT) experiments to reconstitute LDL receptor null mice [LDL-R(-/-)] with marrow obtained from LDL-R wild-type ...
The results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis ...
How to cite websites, books, podcasts, articles, journals, movies, and more in Bone Marrow Transplantation style. Bone Marrow Transplantation Example. A referencing guide from Citationsy, the worlds best reference management tool.
Intravenous literature: Wiersma, P., Schillie, S., Keyserling, H., Watson, J.R., De, A., Banerjee, S.N., Drenzek, C.L., Arnold, K.E., Shivers, C., Kendrick, L., Ryan, L.G., Jensen, B., Noble-Wang, J. and Srinivasan, A. (2010) Catheter-Related Polymicrobial Bloodstream Infections among Pediatric Bone Marrow Transplant Outpatients, Atlanta, Georgia, 2007. Infection Control & Hospital Epidemiology. 31, [ePub ahead of print]. Abstract:. Objective: To identify risk factors for polymicrobial bloodstream infections (BSIs) in pediatric bone marrow transplant (BMT) outpatients attending a newly constructed clinic affiliated with a children’s hospital.. Methods: All 30 outpatients treated at a new BMT clinic during September 10â€21, 2007, were enrolled in a cohort study. The investigation included interviews, medical records review, observations, and bacterial culture and molecular typing of patient and environmental isolates. Data were analyzed using exact conditional logistic ...
Established in 1911, The University of Tennessee Health Science Center aims to improve human health through education, research, clinical care and public service. The UT Health Science Center campuses include colleges of Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing and Pharmacy. Patient care, professional education and research are carried out at hospitals and other clinical sites across Tennessee. Endowed professorships, Research Centers of Excellence, and continuing relationships with research and healthcare facilities across Tennessee ensure that both basic science and applied research stay focused on contemporary health topics.
Pediatr Dent. 1989 Mar;11(1):37-42. Clinical Trial; Controlled Clinical Trial; Research Support, Non-U.S. Govt; Research Support, U.S. Govt, P.H.S.
GHN Healthcare Services is a leading Medical treatment Assistance Company based in New Delhi (National Capital region), India. The Organization actively engaged in providing Medical assistance to foreign Patients who choose to travel to India for quality medical care at a reasonable cost. GHN Healthcare Services is associated with 25+ Top-Notch Hospitals and has a network of 500+ Super Specialists to offer world-class medical care at a reasonable cost.
We analyzed the clinical course and risk factors of 18 patients with poor engraftment after allogeneic bone marrow transplantation (BMT), defined as absolute neutrophil count below 0.1×10 9/1 28 days post-BMT. Significant risks associated with non-engraftment included HLA one antigen mismatch, BMT from matched unrelated donor, and a low dose of colony-forming units-granulocyte-macrophage (,10 4/kg). Examined by a semi-quantitative analysis of polymorphic microsatellite markers, donor DNA chimerism on day 28 was found to be predictive of treatment outcome. Seven patients had detectable donor DNA, varying from 43 to 100%. Five of them responded to granulocyte colony-stimulating factor (G-CSF) and achieved engraftment. Two were given further infusions of peripheral blood hematopoietic stem cells (PBSC) from the same donors, resulting in engraftment in one of them. Eleven patients had no detectable donor DNA, and none responded to G-CSF. Autologous regeneration occurred in six of these patients, ...
Our first blog post highlights the life-saving bone marrow transplant procedure.. The Important Work of a Bone Marrow Transplant. For patients with certain conditions such sickle cell disease, lymphoma, aplastic anemia, and neuroblastoma, myelodysplastic syndrome (MDS), and including possible fatal blood cancers, like lymphoma and leukemia, a bone marrow transplant offers a chance for a cure and a longer life. Its also sometimes necessary to repair damaged marrow (where blood cells are manufactured) as a result of chemotherapy for cancer, as was the case with Good Morning Americas host Robin Roberts. We are happy to hear that Robin is expected back to Good Morning Amerca on February 20th after taking time off for her bone marrow transplant.. Bone Marrow Transplant Donor Awareness. The largest U.S. registry for bone marrow donors Be The Match National Marrow Donor Program encourages people to get involved or volunteer. Be The Match helps to connect donor matches with patients in need of a ...
Fludarabine is a nucleoside analog with potent antitumor and immunosuppressive properties used in conditioning regimens of pediatric allogeneic hematopoietic cell transplantation (alloHCT) to promote stem cell engraftment.. This is a single-center, pharmacokinetic-pharmacodynamic (PK-PD) study investigating the clinical pharmacology of fludarabine in 45 children undergoing alloHCT at UCSF Benioff Childrens Hospital.. Patients would receive fludarabine regardless of whether or not they decide to consent to PK sampling.. Fludarabine doses will not be adjusted based on PK data.. We will apply the combination of a D-optimality-based limited sampling strategy and population PK methodologies to determine specific factors influencing fludarabine exposure in pediatric alloHCT recipients and identify exposure-response relationships.. Subjects will undergo PK sampling of plasma (f-ara-a) and intracellular (f-ara-ATP) drug concentrations over the duration of fludarabine therapy (3 to 5 days).. To evaluate ...
The analysis of the T cell repertoires involved in local or systemic immune responses is beginning to play an important role in many clinical situations. These include autoimmunity, response to viral or bacterial superantigens, alloimmunity including allograft rejection, and tumor immunity. Here we analyze circulating T cell repertoires by determining TCR beta-chain gene complexity using a modification of V beta family-specific PCR. This approach, called CDR3 size spectratyping, uses the size heterogeneity of the CDR3 as a further source of specificity in TCR analysis. It has been used here to analyze the complexity and stability of circulating T cell repertoires in normal adults, including bone marrow donors, and bone marrow transplant recipients. Normal spectratypes are both complex and stable. The repertoire complexity of marrow recipients correlates with their state of immune function. Contractions and gaps in repertoires are revealed in individuals suffering from recurrent infections ...
Question - Successful bone marrow transplant for AML. Now have back pain, cough, loss of appetite. Why?. Ask a Doctor about Bone marrow transplant, Ask an Oncologist
Allogeneic bone marrow transplantation (stem cell transplant) in aplastic anemia (costs for program #80341) ✔ Andreasklinik Cham Zug ✔ Department of Oncology and Hematology ✔
Allogeneic bone marrow transplantation (stem cell transplant) in acute lymphoblastic leukemia (ALL) (costs for program #260823) ✔ University Hospital Münster ✔ Department of Hematology, Hemostaseology, Oncology and Pneumology (Medical Department A) ✔
TY - JOUR. T1 - Percutaneous endoscopic gastrostomy tubes in pediatric bone marrow transplant patients. AU - Kaur, Sunpreet. AU - Ceballos, Clare. AU - Bao, Ruijun. AU - Pittman, Nanci. AU - Benkov, Keith. PY - 2013/3/1. Y1 - 2013/3/1. N2 - BACKGROUND AND OBJECTIVES:: Nourishing a child undergoing bone marrow transplant (BMT) is essential, but the optimal method to achieve this is not established. The objectives of the study were to investigate the incidence and risk factors for complications of gastrostomy tubes in patients with BMT. METHODS:: A retrospective chart review was conducted of pediatric patients who received a percutaneous endoscopic gastrostomy (PEG) either for BMT or for other indications during a 3-year period. Occurrences of complications, absolute neutrophil count (ANC) at time of PEG placement, and ANC at time of complication were reviewed for both BMT and the comparison group. RESULTS:: Of the 11 subjects in the BMT group, 4 (36%) had a major complication of infection related ...
Looking for online definition of autologous bone marrow transplantation in the Medical Dictionary? autologous bone marrow transplantation explanation free. What is autologous bone marrow transplantation? Meaning of autologous bone marrow transplantation medical term. What does autologous bone marrow transplantation mean?
Despite a growing understanding of the link between intestinal inflammation and resident gut microbes, longitudinal studies of human flora before initial onset of intestinal inflammation have not been reported. Here, we demonstrate in murine and human recipients of allogeneic bone marrow transplantation (BMT) that intestinal inflammation secondary to graft-versus-host disease (GVHD) is associated with major shifts in the composition of the intestinal microbiota. The microbiota, in turn, can modulate the severity of intestinal inflammation. In mouse models of GVHD, we observed loss of overall diversity and expansion of Lactobacillales and loss of Clostridiales. Eliminating Lactobacillales from the flora of mice before BMT aggravated GVHD, whereas reintroducing the predominant species of Lactobacillus mediated significant protection against GVHD. We then characterized gut flora of patients during onset of intestinal inflammation caused by GVHD and found patterns mirroring those in mice. We also ...
TY - JOUR. T1 - Caregiver responses and needs. T2 - An ambulatory bone marrow transplant model. AU - Grimm, Patricia M.. AU - Zawacki, Kristin L.. AU - Mock, Victoria. AU - Krumm, Sharon. AU - Frink, Barbara B.. N1 - Copyright: Copyright 2013 Elsevier B.V., All rights reserved.. PY - 2000. Y1 - 2000. N2 - PURPOSE: This longitudinal, descriptive outcomes study was conducted to compare the emotional responses and needs of the caregivers of patients who undergo bone marrow transplantation (BMT) for hematologic malignancies, as observed in an inpatient/outpatient (IPOP) setting with those in an inpatient setting. DESCRIPTION OF STUDY: A convenience sample of 43 caregivers for patients undergoing either autologous or allogeneic BMT was selected from both the inpatient unit (n = 26) and the IPOP ambulatory setting (n = 17). Emotional responses were measured by the Profile of Mood States. The importance and satisfaction of informational, patient-care, and psychological needs were assessed with the ...
Allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen (HLA)-identical donor is currently the only proven curative treatment for chronic granulomatous disease. Hematopoietic stem cell transplantation with alternative donors is associated with higher morbidity and mortality. Therefore, we performed in vitro fertilization and preimplantation HLA matching combined with female sexing for hematopoietic stem cell transplantation in chronic granulomatous disease. Ethical and psychological issues were considered carefully. We used in vitro fertilization with X-enriched spermatozoa followed by preimplantation genetic diagnosis to identify female HLA-genoidentical embryos in a family in need of a suitable donor for their boy affected with severe X-linked chronic granulomatous disease. Two preimplantation genetic diagnosis cycles were performed in the family. In the second cycle, 2 HLA-genoidentical female embryos were transferred and a singleton pregnancy was obtained, ...
TY - JOUR. T1 - Autologous blood stem cell versus bone marrow transplantation. AU - Korbling, M.. AU - Juttner, C.. AU - Henon, P.. AU - Kessinger, A.. PY - 1992. Y1 - 1992. UR - UR - M3 - Article. C2 - 1355683. AN - SCOPUS:0026752883. VL - 10. SP - 144. EP - 148. JO - Bone Marrow Transplantation. JF - Bone Marrow Transplantation. SN - 0268-3369. IS - SUPPL. 1. ER - ...
TY - JOUR. T1 - Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. AU - Katsanis, E.. AU - Anderson, P. M.. AU - Filipovich, A. H.. AU - Hasz, D. E.. AU - Rich, M. L.. AU - Loeffler, C. M.. AU - Ochoa, A. C.. AU - Weisdorf, D. J.. N1 - Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 1991. Y1 - 1991. N2 - We evaluated the proliferation, cytolytic function, and phenotypic characteristics of anti-CD3 plus interleukin-2 (IL-2) stimulated peripheral blood mononuclear cells (PBMCs) from 44 patients with leukemia or non-Hodgkins lymphoma (NHL) treated with multiagent chemotherapy or following bone marrow transplantation (BMT). BMT patients had decreased cell growth with only a 1.35 ± 0.25 (autologous BMT for acute lymphoblastic leukemia [ALL]), 1.24 ± 0.25 (autologous BMT for NHL), and 0.8 ± 0.1 (allogeneic BMT for leukemia) mean fold increase by day 5 of culture compared with ...
Pediatric anaplastic large cell lymphoma (ALCL) is a chemosensitive malignancy, but about 30% of patients experience relapse. In most of these patients, a second complete remission is obtainable with salvage chemotherapy, though relapse free survival rates are as low as 30-60%. Herein, we report a 6-year-old boy with relapsed anaplastic lymphoma kinase (ALK) positive ALCL successfully treated with vinblastine monotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reduced intensity conditioning (RIC) regimen, from his father. One HLA locus from the father was mismatched. The boy had neither severe graft-versus-host disease nor transplantation related complications. He is currently well and has remained disease free for 10 months, to date, since transplantation. Allo-HSCT with a RIC regimen may be a promising treatment strategy for relapsed ALK positive ALCL based on obtaining graft-versus lymphoma effects as well as reducing transplantation-related mortality.
A 16 year old man underwent an allogeneic bone marrow transplantation (BMT) from an HLA identical sibling donor for acute lymphoblastic leukaemia in 1984. He developed chronic graft versus host disease involving the skin and kidneys. At day 400 after BMT his condition was complicated by obstructive airways disease, which was partially responsive to azathioprine and steroids. Five years after withdrawal of immunosuppressive treatment he developed dyspnoea and decreased pulmonary function test results, and steroid treatment was resumed. Fibrobronchoscopy revealed the presence of a mucoepidermoid carcinoma in the left main bronchus. After surgical laser resection, there was gradual clinical and functional improvement. There was no evidence of recurrence one year after surgery.. ...
Looking for online definition of bone marrow transplant in the Medical Dictionary? bone marrow transplant explanation free. What is bone marrow transplant? Meaning of bone marrow transplant medical term. What does bone marrow transplant mean?
TY - JOUR. T1 - Allogeneic bone marrow transplantation for chronic granulomatous disease. AU - Rappeport, Joel M.. AU - Newburger, Peter E.. AU - Goldblum, Randall M.. AU - Goldman, Armond S.. AU - Nathan, David G.. AU - Parkman, Robertson. PY - 1982/12. Y1 - 1982/12. UR - UR - U2 - 10.1016/S0022-3476(82)80017-6. DO - 10.1016/S0022-3476(82)80017-6. M3 - Article. C2 - 6754900. AN - SCOPUS:0020385877. VL - 101. SP - 952. EP - 955. JO - Journal of Pediatrics. JF - Journal of Pediatrics. SN - 0022-3476. IS - 6. ER - ...
AIMS--To study the association between cytomegalovirus (CMV) excretion and interstitial pneumonitis in allogeneic bone marrow transplant (BMT) recipients, with reference to donor and recipient CMV antibody response. METHODS--The incidence of CMV excretion was prospectively studied in 62 allogeneic bone marrow transplantations performed on adults and children. All recipients received CMV seronegative blood products. Prophylaxis with high dose acyclovir and CMV immune globulin was given to high risk patients (donor or recipient, or both, CMV seropositive). RESULTS--CMV excretion was detected in eight of 26 (31%) high risk patients but in only one of 36 low risk patients (donor and recipient both CMV seronegative). Five of the eight (63%) excretors in the high risk category developed CMV, of whom four (80%) belonged to the seropositive recipient/seronegative donor group, and included the three CMV seropositive recipients whose CMV complement fixation antibody titres were 64 or greater before ...
Background: Given the presumed key role for autoreactive lymphocytes in multiple sclerosis (MS), treatment strategies have been developed to ablate lymphocyte activity. Intrathecal lymphocyte activation can be measured by CSF-soluble(s)CD27.. Objective: To determine the effect of maximum whole-body immune ablation on two different markers that detect lymphocyte activation in CSF-oligoclonal IgG bands and levels of CSF-sCD27.. Design, setting and patients: The study quantified sCD27 levels and assessed the presence of oligoclonal IgG bands in CSF samples of secondary progressive patients with MS treated by autologous bone-marrow transplantation. In eight individuals, CSF was taken before and 6-9 months after conditioning. CSF-sCD27 levels were compared with other MS and non-inflammatory neurological disease controls. Regarding the effect of stem-cell transplantation on CSF oligoclonal bands, the study analysed pooled data of this and four other international studies on stem-cell transplantation ...
Infections are responsible for a large part of the morbidity and mortality after BMT because of the sustained impairment of host defenses. We report a case of cutaneous infection caused by Mycobacterium szulgai in a boy who underwent BMT with marrow from a matched unrelated donor.. ...
Fingerprint Dive into the research topics of Detection of HHV-6B in post-mortem central nervous system tissue of a post-bone marrow transplant recipient: a multi-virus array analysis.. Together they form a unique fingerprint. ...
View details of top bone marrow transplantation hospitals in Ambience Island, Gurgaon. Get guidance from medical experts to select best bone marrow transplantation hospital in Ambience Island
Dr. Dharma Choudhary, Best Doctor in India, Best Bone Marrow Transplant specialist in B L Kapur Hospital, New Delhi, Bone marrow Transplant in Specialist in India, Doctor for Bone Marrow Transplant in India, Health in India, Hematologist at B L Kapur Hospital, new Delhi, Hematologist in Delhi. Bone Marrow Transplant in Delhi, Hospital for bone marrow transplant in India
Different Asthma Phenotypes in Adult Asthma: Comparison of Allergic Asthma and Nonallergic Asthma Chih-Hao Chang, Horng-Chyuan Lin, Meng-Heng Hsieh, Guan-Yuan Chen, Fu-Tsai Chung, Chih-Teng Yu, Han-Pin Kuo Anti-inflammatory Activity and Mucolytic Effect of Ambroxol in Patients with Stable Chronic Bronchitis ─ A Preliminary Report Chien-Ming Chu, Chung-Chieh Yu, Huang-Ping Wu, Bor-Yiing Jiang, Jo-Chi Tseng, Chung-Ching Hua, Teng-Jen Yu, Yu-Chih Liu, Wen-Pin Shieh Spontaneous Remission in Goodpasture Syndrome and Relapse 5 Years Later - A Case Report Fang-Chuan Dai, Mei-Chin Wen, Jeng-Yuan Hsu, Gwan-Han Shen IgG4-Related Sclerosing Disease of the Lung ─ Case Report Chih-Heng Kuo, Wen-Hu Hsu, Yi-Chen Yeh Wegeners Granulomatosis with Tracheal Involvement and Severe Pulmonary Hemorrhage Hui-Wen Shih, Hou-Tai Chang, Cheng-Yu Chang, Shin-Lung Cheng Late Onset Non-Infectious Interstitial Lung Disease Following Bone Marrow Transplantation: A Case Report Mei-Ling Chen, Yung-Hsiang Hsu, En-Ting Chang
TY - JOUR. T1 - Therapeutic angiogenesis by bone marrow mononuclear cell transplantation. T2 - limitation in the elderly and augmentation by angiopoietin 1 gene therapy. AU - Kondo, Takahisa. AU - Kobayashi, Koichi. AU - Inoue, Natsuo. AU - Izawa, Hideo. AU - Shintani, Satoshi. AU - Okumura, Kenji. AU - Murohara, Toyoaki. AU - Numaguchi, Yasushi. N1 - Copyright: MEDLINE® is the source for the citation and abstract of this record.. PY - 2007/1. Y1 - 2007/1. UR - UR - U2 - 10.3143/geriatrics.44.65. DO - 10.3143/geriatrics.44.65. M3 - Review article. C2 - 17337854. AN - SCOPUS:34047248695. VL - 44. SP - 65. EP - 68. JO - Japanese Journal of Geriatrics. JF - Japanese Journal of Geriatrics. SN - 0300-9173. IS - 1. ER - ...
In an effort to find new strategies to personalize treatment for pediatric patients, Seattle Childrens has opened the first clinical trial applying next-generation T-cell receptor (TCR) sequencing and single-cell gene expression analysis to better understand how the immune system drives both inflammatory bowel disease (IBD) in pediatric autoimmunity patients and graft-versus host disease (GVHD) in pediatric bone marrow transplant (BMT) patients.. The PREDICT (Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation) trial is expected to first provide clinicians new information about why IBD arises in children, allowing them to tailor treatment plans to each patient. The trial will later expand to include BMT patients with the goal of identifying the immunologic changes that occur when a patient develops GVHD, the deadliest complication associated with BMT. BMT is used to treat a range of pediatric conditions from leukemia to inherited bone marrow failure ...
TY - JOUR. T1 - Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function. T2 - The LateTIME randomized trial. AU - Traverse, Jay H.. AU - Henry, Timothy D.. AU - Ellis, Stephen G.. AU - Pepine, Carl J.. AU - Willerson, James T.. AU - Zhao, David X.M.. AU - Forder, John R.. AU - Byrne, Barry J.. AU - Hatzopoulos, Antonis K.. AU - Penn, Marc S.. AU - Perin, Emerson C.. AU - Baran, Kenneth W.. AU - Chambers, Jeffrey. AU - Lambert, Charles. AU - Raveendran, Ganesh. AU - Simon, Daniel I.. AU - Vaughan, Douglas E.. AU - Simpson, Lara M.. AU - Gee, Adrian P.. AU - Taylor, Doris A.. AU - Cogle, Christopher R.. AU - Thomas, James D.. AU - Silva, Guilherme V.. AU - Jorgenson, Beth C.. AU - Olson, Rachel E.. AU - Bowman, Sherry. AU - Francescon, Judy. AU - Geither, Carrie. AU - Handberg, Eileen. AU - Smith, Deirdre X.. AU - Baraniuk, Sarah. AU - Piller, Linda B.. AU - Loghin, Catalin. AU - Aguilar, ...
Hill, GR, Ferrara, JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. vol. 95. 2000. pp. 2754-9. (Highlights the importance of the gastrointestinal tract in the pathogenesis of GVHD). Przepiorka, D, Weisdorf, D, Martin, P. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. vol. 15. 1995. pp. 825-8. (Key article on grading of acute GVHD). Cahn, JY, Klein, JP, Lee, SJ. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. vol. 106. 2005. pp. 1495-1500. (Key article on grading of acute GVHD). Eapen, M, Horowitz, MM, Klein, JP. Higher mortality after allogeneic peripheral-blood transplantation compared with bone ...
TY - JOUR. T1 - Donor bone marrow infusions are tolerogenic in human renal transplantation. AU - Ciancio, G.. AU - Garcia-Morales, R.. AU - Mathew, J.. AU - Carreno, M.. AU - Burke, G. W.. AU - Ricordi, C.. AU - Kenyon, N.. AU - Esquenazi, V.. AU - Cirocco, R.. AU - Tzakis, A.. AU - Miller, J.. PY - 2001/1/1. Y1 - 2001/1/1. UR - UR - U2 - 10.1016/S0041-1345(00)02485-4. DO - 10.1016/S0041-1345(00)02485-4. M3 - Article. C2 - 11267299. AN - SCOPUS:0035087150. VL - 33. SP - 1295. EP - 1296. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 1-2. ER - ...
bone marrow donor programme - List of free articles written by article author bone marrow donor programme which can be reprinted or published on your blog, website or ezine.
Approaches for haploidentical bone marrow transplantation (BMT) without T-cell depletion have been designed using new transplant strategies, including anti-thymocyte globulin (ATG) preparative regimens, granulocyte colony-stimulating factor-primed grafts, post-transplantation rapamycin, or high-dose cyclophosphamide (Cy) in combination with other immunosuppressive agents for graft-versus-host disease (GVHD) prophylaxis. These strategies ensured fast hematologic engraftment across the human leukocyte antigen (HLA) barrier with an acceptable incidence of GVHD. Long-term follow-up results from different transplant centers suggest that unmanipulated transplantation may provide an alternative strategy in the haploidentical setting without requiring the technical expertise and cost of ex vivo T-cell depletion. This review discusses immune reconstitution and factors associated with clinical outcomes following unmanipulated haploidentical hematopoietic stem cell transplantation (HSCT), and compares ...
Leading Bone Marrow Transplant Specialist and doctor in India talks about bone marrow transplant or BMT, Stem Cell Transplant treatment for thalassemia, leukemia, sickle-cell disease and few other diseases in India for international patients looking for BMT or bone marrow transplant or stem cell transplant hospitals and doctors in India. Bone Marrow Transplant Package cost in India. The rest is here ...
CORTICOSTEROIDS. Corticosteroids have been the mainstay treatment for NMO in both acute and maintenance phase. Methylprednisolone has been used since 1970 as a potent anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of hematologic, allergic, inflammatory, neoplastic and autoimmune origin. In addition, it is also widely used in prevention and treatment of graft-versus-host disease following allogeneic bone marrow transplantation and acute spinal cord injury. Corticosteroids exert a wide array of physiologic effects including modulation of carbohydrate, protein and lipid metabolism, and maintenance of fluid and electrolyte homeostasis. Moreover, cardiovascular, immunologic, musculoskeletal, endocrine and neurologic physiologic functions are influenced by corticosteroids. Therefore, not only the positive effects can be observed, but also many adverse events can be originated from corticosteroids use. These adverse events can be seen acutely like ...
TY - JOUR. T1 - Therapeutic effects of concurrent autologous bone marrow cell infusion and metabolic intervention in ischemia-induced angiogenesis in the hypercholesterolemic mouse hindlimb. AU - de Nigris, Filomena. AU - Williams-Ignarro, Sharon. AU - Sica, Vincenzo. AU - DArmiento, Francesco P.. AU - Lerman, Lilach O.. AU - Byrns, Russell E.. AU - Sica, Giacomo. AU - Fiorito, Carmela. AU - Ignarro, Louis J.. AU - Napoli, Claudio. PY - 2007/4/25. Y1 - 2007/4/25. N2 - Lower-limb ischemia is a major health problem especially when associated to hypercholesterolemia. Because of the absence of effective treatment in the advanced stages of the disease, amputation is undertaken to alleviate unbearable symptoms. Since tissue ischemia and hypercholesterolemia are associated with an overwhelming generation of oxygen radicals, metabolic intervention with antioxidants and l-arginine can induce beneficial effects beyond those achieved by a novel therapeutic approach represented by the use of autologous ...
Some people experience bone marrow problems and their bone marrow is destroyed. It is the semi-solid tissue that is found in the spongy areas of bones. Some diseases of the bone marrow are not curable such as multiple myeloma. So, this part should be replaced. The bone marrow transplant procedure is performed to the patients who experience severe problems such as cancer. So, they take cells that are normally found in bone marrow and these cells are filtered. If these cells become germ-free after filtering, then they are placed in the same location of the patient. Otherwise, the cells of other persons are transplanted in the region. Bone marrow transplant The bone marrow produces three types of cells namely the red blood, white blood and platelets. This operation involves complications also and sometimes, it is life-threatening. Some of the complications that arise are graft host disease and graft failure. The blood forming cells of the patient are extracted and replaced with the germ-free ...
TY - JOUR. T1 - Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice. AU - Siefer, Anne K.. AU - Longo, Dan L.. AU - Harrison, Christie Lee. AU - Reynolds, Craig W.. AU - Murphy, William J. PY - 1993/10/15. Y1 - 1993/10/15. N2 - Purified populations of natural killer (NK) cells were obtained from mice with severe combined immune deficiency (SCID). SCID spleen cells were cultured and activated with recombinant human interleukin-2 (rhIL-2) in vitro. The activated NK cells were then transferred with syngeneic BALB/c bone marrow cells (BMC) and rhIL-2 into lethally irradiated syngeneic recipients to determine their effect on long-term hematopoietic reconstitution. On analysis, the transfer of rhIL-2-activated NK cells along with BMC resulted in significant increases in splenic and BM hematopoietic progenitor cells when compared with those for mice not receiving NK cells. Histologic and flow ...
The Transplant Committee of the Cancer and Leukemia Group B (CALGB) was organized in the mid-1980s at a time when high-dose chemotherapy with autologous bone marrow transplant was being actively investigated as treatment for a number of solid tumors and hematologic malignancies. Preliminary data from single institution studies had generated considerable interest in the use of high-dose chemotherapy and autologous bone marrow transplant for both metastatic and early-stage high-risk breast cancer, so that such treatment was widely employed at many centers despite the lack of definitive evidence from controlled trials that it was efficacious. Therefore, CALGB designed protocol 9082 to definitively test whether high-dose chemotherapy and autologous bone marrow transplant was superior to intermediate dose chemotherapy in women with stage II breast cancer and ≥10 positive axillary lymph nodes (1).. At the time this trial was initiated, the role of autologous transplantation as treatment for ...
TY - JOUR. T1 - Pharmacodynamic studies of cyclosporine in marrow transplant recipients. T2 - A comparison of three assay methods. AU - McGuire, Timothy R. AU - Yee, Gary C. AU - Emerson, S.. AU - Gmur, D. J.. AU - Carlin, J.. PY - 1992/1/1. Y1 - 1992/1/1. N2 - We investigated the correlation between trough cyclo-sporine concentration in plasma measured by polyclonal fluorescence polarization immunoassay (FPIA) and polyclonal radioimmunoassay (RIA) or in whole blood measured by high-performance liquid chromatography (HPLC) and the risk of renal dysfunction or acute graft-versus-host disease in 29 patients undergoing allogeneic bone marrow transplantation for leukemia. The FPIA and RIA values were highly correlated (r=0.93) and on the average CsA concentrations measured by FPIA were 1.56 times higher than those measured by RIA. Ten patients developed renal dysfunction and 10 developed grades II-IV acute GVHD. Although univariate analysis showed that plasma CsA concentrations measured by either ...
SEATTLE - Study demonstrates that marrow transplantation using HLA-matched unrelated donors can be safe and effective therapy for patients with chronic myeloid leukemia (CML) in chronic phase. Seattle researchers also believe that transplantation should not be limited to younger people, under the age of 40 years. Fred Hutchinson Cancer Research Center researchers published the results of their study in the April 2, 1998, issue of The New England Journal of Medicine.. Transplantation has been shown to be the cure for many blood disorders and inherited diseases, including CML. One obstacle has always been the identification of a suitably matched donor. Previously, it was believed that only those CML patients with an HLA-matched sibling donor had an option for curative treatment. This study concludes that marrow transplantation from an HLA-matched unrelated donor can be the treatment of choice for many CML patients and should be considered early in the course of disease to optimize ...
Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy.. Stem cell transplant is used to produce blood in the body and also some other components for persons immune system to work. Persons stem cells are recovered and harvested in a system. These cells were then put back into the body intravenously.. For more information about bone marrow stem cell transplant and stem cell therapies, contact us. Its free!. Simply click the button below. ...
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia This study is currently recruiting participants. Verified April 2012 by…
Results:. Three and one half years after single-dose TBI, 51 of the 74 patients (69%) were alive and cataracts had developed in all of these 51 patients. Cataracts developed in 18 of the 90 (20%) patients treated with fractionated TBI, with an 83% (95% CI, 63% to 100%) risk for lens opacification at 6 years\f. Cataracts developed in only 1 of the 33 (3%) patients treated with chemotherapy alone. Incidence of cataracts is higher and lens opacification occurs earlier after single-dose TBI than after fractionated TBI (P , 0.01). With Cox regression analysis, the use of irradiation (relative risk, 21.0), the mode of irradiation (relative risk, 7.4), and the use of steroid treatment (relative risk, 2.9) for more than 3 months after bone marrow transplantation increased the risk for cataract formation. In contrast, age, sex, and chronic graft-versus-host disease did not influence the rate of cataract development. The probability of requiring cataract surgery after 6 years was 85% (CI, 75% to 95%) for ...
AIMSSerum concentrations of tumour necrosis factor-alpha (TNF) were determined in beta thalassemic patients before and after bone marrow transplantation (BMT) to evaluate whether changes in TNF concentrations after BMT were related to immune mediated complications.METHODSSerum TNF concentrations were determined by enzyme linked immunoassay (EIA) in paired samples from 71 patients with beta thalassemia before and after BMT. Serial samples from 13 patients were also studied for up to six months after BMT. Forty one normal healthy children matched for sex and age were studied as controls.RESULTSbeta thalassemic patients had high serum TNF concentrations before transplantation compared with controls. These were not related to sex, age, duration of disease, number of blood transfusions, transferrin concentrations or splenectomy. DQw1 positive patients showed significantly lower TNF concentrations than non-DQw1 cases. Patients with severe liver fibrosis had significantly higher TNF concentrations. No ...
definition of ABMR, what does ABMR mean?, meaning of ABMR, Autologous Bone Marrow Reinfusion, ABMR stands for Autologous Bone Marrow Reinfusion
This phenomenon is used in bone marrow transplantation, when a small number of Hematopoietic stem cells reconstitute the ... In adults, haematopoiesis occurs in the red bone marrow, in the core of most bones. The red bone marrow is derived from the ... may travel in the blood from the bone marrow in one bone to another bone. If they settle in the thymus, they may develop into T ... This process indicates that, subsequent to bone marrow transplantation, symmetrical cell divisions into two daughter ...
Bone Marrow Transplantation. 32 (4): 391-8. doi:10.1038/sj.bmt.1704152. PMID 12900775. Lee E, Min HK, Oskeritzian CA, Kambe N, ... in bone marrow, to immature neutrophils". Comptes Rendus de l'Académie des Sciences, Série III. 324 (12): 1125-32. doi:10.1016/ ... "Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation". ...
Bone Marrow Transplantation. 31 (5): 361-369. doi:10.1038/sj.bmt.1703816. PMID 12634727. FLT3 signaling. ...
"Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome". Bone Marrow Transplantation. 47 (11): 1428 ... bone marrow, or peripheral blood following treatment with medications that cause stem cells to leave the bone marrow and ... Mullen, CA; Anderson, KD; Blaese, RM (1993-11-15). "Splenectomy and/or bone marrow transplantation in the management of the ... It contains 502 amino acids and is mainly expressed in hematopoietic cells (the cells in the bone marrow that develop into ...
"How to avoid bias when comparing bone marrow transplantation with chemotherapy". Bone Marrow Transplantation. 7 Suppl 3: 9-12. ...
"Bordetella bronchiseptica pneumonia and bacteremia following bone marrow transplantation". J Clin Microbiol. 30 (9): 2474-5. ...
citation needed] Autologous bone marrow transplantation is currently being investigated.[citation needed] Hepatosplenic ... Treatment solely with doxorubicin can make the disease worse.[citation needed] Allogeneic bone marrow transplantation has been ... While the bone marrow is commonly involved, the detection of the neoplastic infiltrate may be difficult due to a diffuse, ... The spleen and liver are always involved, and bone marrow involvement is common. Nodal involvement is exceedingly rare. The ...
"Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation". Arch Dermatol. 122 (9): 1023-7. doi: ... The problem can also arise in patients after bone marrow transplants, as the clinical and histologic features of PPE can be ...
Typing for these polymorphisms is routinely done for bone marrow transplantation. There are four commonly encountered DQA1 ...
... was a renowned expert in bone marrow transplantation. He became interested in bone marrow transplantation ... He founded the Johns Hopkins Oncology Center's bone marrow transplant program and served as its director from 1968 until his ... treatments to prevent and manage opportunistic infections in immuno-compromised bone marrow transplant patients; techniques in ... His other research were: The use of the drug 4-HC to purge patients' diseased marrow of cancer cells, allowing them to self- ...
Typing for these polymorphisms is routinely done for bone marrow transplantation. Several alleles of HLA-DQB1 are associated ...
Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation In National Cancer Institute Fact Sheet web site. ... Bone marrow transplantation is a widely used form of stem cell therapy. No other forms of stem cell therapy are in clinical use ... A recurring sub-theme of cloning fiction is the use of clones as a supply of organs for transplantation. Robin Cook's 1997 ... This type of medicine would allow for autologous transplantation, thus removing the risk of organ transplant rejection by the ...
Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. DRB1 is expressed at a level five ...
Allogenic bone marrow transplantation is possible and genetic therapy is currently under development. The most frequent CGD ...
The transplantation of bone marrow has also been conducted as a treatment option. There is a natural way the body tries to ...
Bone Marrow Transplantation for Breast Cancer: Bone Marrow Transplantation for Breast Cancer. Oxford University Press. p. 183. ...
At the moment there exists only one treatment for OS which is bone marrow transplantation. If no treatment is performed OS is ...
More specifically, the first MiHA was discovered when bone marrow transplantation occurred between opposite sexes. The female ... The CD8+ T cells were active and targeted the male bone marrow cells. The male bone marrow cells were found to be presenting a ... Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors". Bone Marrow Research. 2012 ... Although graft or bone marrow rejection can have detrimental effects, there are immunotherapy benefits when cytotoxic T ...
... see also allogeneic stem cell transplantation, allogeneic bone marrow transplantation, allotransplantation) with double-delta- ... Bone marrow transplantation and organ transplants in general have been found to introduce foreign DNA into patients. Gene ... Bone marrow transplants are the only cure for thalassemia, but 75% of patients do not find a matching donor. Cancer immunogene ... They were also given bone marrow. One patient relapsed and died and one died of a blood clot unrelated to the disease. ...
"Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma". ... bone marrow, feces, red blood cells, and urine. Though expressivity is varied depending on the mutation responsible for ...
Those who attain a complete response on this drug and can tolerate it are than treated with bone marrow transplantation. ... transplantation using the individuals own bone marrow, i.e. autologous, or a donor's, i.e. allogenic) after achieving a ... employ allogeneic bone marrow transplantation for patients with multiple relapses that have progressed on systemic therapy. ... bone (14%), soft tissues (15%), lung (12%), and/or liver (8%). Tumor cells are found in the bone marrow in up to 40% of the ...
2005). "Minor histocompatibility antigen HA-1 and HPA-5 polymorphisms in HLA-identical related bone marrow transplantation". ... 2002). "Expression of minor histocompatibility antigen, HA-1, in solid tumor cells". Transplantation. 73 (7): 1137-1141. doi: ... 2007). "HA-1 mismatch has significant effect in chronic allograft nephropathy in clinical renal transplantation". Transplant. ... a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation". Blood. 100 (2): 547-552. doi: ...
Bone marrow transplantation (BMT) and umbilical cord blood transplantation (UCBT) can be used as treatments for MPS I. BMT from ... Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four ... Patients who received successful bone marrow transplants had a 2-year survival rate of 68% and a 10-year survival rate of 64%. ... Children often lack access to a suitable bone marrow donor. In these cases, UCBT from unrelated donors can increase survival, ...
... bone marrow into a Hoxb8 mutant mouse results in a reduction of compulsive grooming. Homeobox GRCh38: Ensembl release 89: ... This behavior is similar to the hair-pulling behavior of humans suffering from trichotillomania (TTM). Transplantation of ...
... are immunodominant minor histocompatibility antigens after bone marrow transplantation". Transplantation. 66 (7): 910-6. doi: ... a history of transplantation, immune response genes, sex determination and expression cloning". Annual Review of Immunology. 15 ...
With the advent of bone marrow transplantation, most cases since its introduction have been in those undergoing treatment for ... is preferred if hepatic veno-occlusive disease happens as a result of chemotherapy or bone marrow transplantation. Apart from ... In the bone marrow transplant setting, hepatic veno-occlusive disease is felt to be due to injury to the hepatic venous ... In those with severe disease due to a bone marrow transplant, defibrotide is a proposed treatment. It has been approved for use ...
General Hospital reported that when antibodies to CD40L induced tolerance in allogeneic bone marrow transplantation, LAG3 was ... Stanford University showed that LAG engagement could diminish alloreactive T cell responses after bone marrow transplantation. ... in conventional and regulatory T cell function in allogeneic transplantation". PLOS ONE. 9 (1): e86551. Bibcode:2014PLoSO... ... In 2011 scientists studying transplantation biology at Massachusetts ...
Lubricin, as MSF, was detected in the urine of patients undergoing bone marrow transplantation during a period of acute ... Zhang D, Johnson LJ, Hsu HP, Spector M (July 2007). "Cartilaginous deposits in subchondral bone in regions of exposed bone in ... The expression of lubricin has also been detected and the protein localized in tendon, meniscus, lung, liver, heart, bone, ...
... alleles have been described and typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. ...
... of T-cell receptor V alpha sequence and variable-joining pairs after normal T-cell development and bone marrow transplantation ...
"Bone marrow as a potential source of hepatic oval cells". Department of Pathology, School of Medicine, University of Pittsburgh ... "History of clinical transplantation". Thomas E. Starzl Transplantation Institute, University of Pittsburgh; Starzl TE. Dibukak ... "History of clinical transplantation". Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center,; ... "Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced ...
Bone Marrow Transplant. 34 (8): 683-91. doi:10.1038/sj.bmt.1704602. PMID 15322567. "{{Webarchive,url= ... indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplantation ...
"Enhanced differentiation of splenic plasma cells but diminished long-lived high-affinity bone marrow plasma cells in aged mice ... Immune system aging in mice can be partly restricted by restoring thymus growth, which can be achieved by transplantation of ...
... of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: ...
... is a combination of syndromes that involves the bone marrow and the exocrine pancreas. Pearson marrow pancreas ... Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD (Autologous cd34+ ... To diagnose Pearson Syndrome a physician can either collect a bone marrow biopsy and look for sideroblastic anemia, a symptom ... With Pearson syndrome, the bone marrow fails to produce white blood cells called neutrophils. The syndrome also leads to anemia ...
... the aggressive chemotherapy and/or bone marrow transplantation used to treat aggressive leukemia may be required. While the ... Bone marrow examination may reveal increases in eosinophils and mast cells but usually does not contain elevated numbers of ... definitive results are obtained by detecting the presence of the FIP1L1-PDGFRA fusion gene in the blood and/or bone marrow ... by the presence of morphologically abnormal or excessive numbers of myeloid or lymphoid cells in the blood or bone marrow and, ...
... a substantial proportion of mice with leukaemia can be cured by whole body irradiation followed by the grafting of bone marrow ... Loutit was the first to recognize 'secondary disease' in irradiated mice restored by the transplantation of foreign cells, and ... His candidature citation read: Distinguished for his experimental studies of tissue transplantation after lethal doses of ...
Acid-alpha glucosidase for Pompe disease Gene therapy Bone marrow or organ transplantation Treatment of symptoms and ... bone marrow Skin biopsy and fibroblast cultivation for specific enzyme testing Specific DNA testing A 2015 review reported that ... In the past twenty years, new medications, enzyme replacement, gene therapy, and organ transplantation have become available ...
... base pair birth defect bone marrow transplantation cancer candidate gene carcinoma carrier cDNA library cell centimorgan ...
... the latter after bone marrow transplantation to prevent graft-versus-host disease, the former also being used in conjunction ... with bone marrow transplantation; sometimes, the two compounds are used concomitantly, exploiting the capacity of cyclosporine ... This drug was to revolutionize organ transplantation in the 1970s and the paper became a citation classic (CC/6:16-16, 6 ... of this procedure initiated an innovative screening system for discovering immunosuppressant drugs lacking bone marrow toxicity ...
"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche". Nature. 438 (7069): 820-7. Bibcode: ... Transplantation. 22 (3): 712-4. doi:10.1093/ndt/gfl768. PMID 17210583. Poesen K, Lambrechts D, Van Damme P, Dhondt J, Bender F ...
... lymphoblastic leukemia with 2 among 3 family members moving rather quickly from chemotherapy to bone marrow transplantation and ... and bone marrow biopsy findings of abnormal appearing megakaryocytes (i.e. nuclei with fewer than the normal number of ... genetic manipulation studies in mice indicate that the gene is required for the development and maintenance of bone marrow- ...
... from a patient's bone marrow and/or spleen are often recommended for confirmation. A bone marrow biopsy involves the removal of ... However, stem cell transplantation is a high-risk procedure, with significant morbidity and mortality rates. Furthermore, it is ... Furthermore, it is most active in the blood, bone marrow and spleen, all of which are main sites involved with B-PLL and thus ... The most common signs and symptoms are the result of the inability of the bone marrow to produce normal levels of blood cells: ...
Bart Roep leads immune intervention strategies (including gene therapy, stem cell therapy and bone marrow transportation[ ... Fouad Kandeel leads clinical trials testing the use of islet transplantation to treat patients who are incapacitated by severe ... "RNA-Based Gene Therapy for HIV with Lentiviral Vector-Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS- ...
... and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression". Blood. 99 (6 ... Wells AD, Li XC, Strom TB, Turka LA (May 2001). "The role of peripheral T-cell deletion in transplantation tolerance". ... Together with osteoblasts, which form new bones, osteoclast helps maintain and repair bone in vertebrates. BLIMP-1 directly and ... Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simões MJ, Cerri PS (2015-07-13). "Biology of Bone Tissue: Structure, Function, and ...
Unlike bone marrow transplantation, cord blood transplantation doesn't require an exact genetic match, which makes it easier to ... Recent studies have shown that cord blood has unique advantages over traditional bone marrow transplantation, particularly in ... Bone marrow transplants require a complete match on six key antigens, which are measures of graft-versus-host reaction, known ... The odds that two siblings will have the 6/6 match required for a bone marrow transplant are 25%. The odds that two siblings ...
However, stem cells with limited potency (adult stem cells) remain in bone marrow, intestine, skin etc. to act as a source of ... the nucleus from a differentiated frog intestinal epithelial cell can generate a fully functional tadpole via transplantation ...
... and other congenital bone marrow failure disorders". The Cochrane Database of Systematic Reviews. 2015 (10): CD011577. doi: ... a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation". ...
Pakistani hematologist and bone marrow pioneer[citation needed] Official Website of Dow University of Health Sciences DOW ... Transplantation Nausheen Hamid - Pakistani politician and social activist, member of the National Assembly of Pakistan Tahir ... philanthropist and head of Sindh Institute of Urology and Transplantation. Sanjay Gangwani - Pakistani Politician Rafat Hussain ...
27 January 2016). "Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells". Nature ... activation or rejection of the liver during liver transplantation and liver fibrosis. They form part of the mononuclear ... However, if resident Kupffer cell populations are depleted, monocytes derived from hematopoietic stem cells in the bone marrow ...
... nearly 2,000 59th MDW personnel work with Army medics in areas such as the bone marrow transplant center, the burn unit, and ... bone banking and transplantation; laser photocoagulation; and acquired immune deficiency syndrome (AIDS). In December 1989, it ...
... and autologous bone marrow transplantation. Between 2000 and 2008 he was the rector of the Vrije Universiteit Brussel. Benjamin ...
Hunt P, Robertson D, Weiss D, Rennick D, Lee F, Witte ON (March 1987). "A single bone marrow-derived stromal cell type supports ... cells is used to expand the number of cells and differentiate the cells into various somatic cell types for transplantation. ... bone cancer) SH-SY5Y (neuroblastoma, cloned from a myeloma) T-47D (breast cancer) THP-1 (acute myeloid leukemia) U87 ( ...
Bone marrow involvement runs the spectrum between an inconspicuous infiltrate to extensive marrow replacement by leukemic cells ... January 2009). "Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a ... and bone marrow. Leukemic cells are invariably present in samples of peripheral blood to a variable extent. Pancytopenia ( ... July 2007). "Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from ...
... obtained from patients with rheumatoid arthritis or during rejection of solid organ transplants and bone marrow transplantation ... TCIRG1 mutations affect the a3 subunit of the vacuolar proton pump, which in turn affects the acidification of the bone- ... Transplantation Proceedings. 33 (1-2): 1610-1. doi:10.1016/S0041-1345(00)02613-0. PMID 11267440. Shulzhenko N, Morgun A, Rampim ... American Journal of Transplantation. 4 (4): 505-14. doi:10.1111/j.1600-6143.2004.00367.x. PMID 15023142. S2CID 36001054. ...
Bone marrow, liver and gastrointestinal tract involvement occurs relatively early in the course of the disease. Mantle cell ... hematopoietic stem cell transplantation), using either autologous stem cell transplantation, or those from a matched donor (an ... For this reason, both the peripheral blood and bone marrow are evaluated for the presence of malignant cells. Chest, abdominal ... MCL may also replace normal cells in the bone marrow, which impairs normal blood cell production.[citation needed] Diagnosis ...
... pioneer in bone marrow transplantation Bob Scheifler - computer scientist, leader of the X Window System project, architect of ...
Among the serious complications associated with bone marrow transplantation are invasive fungal infections caused by organisms ... In bone marrow transplantation patients receiving fluconazole(Diflucan), Marr and colleagues recently reported that ... Among the serious complications associated with bone marrow transplantation are invasive fungal infections caused by organisms ... Prophylaxis Against Fungal Infections and Cytomegalovirus Disease After Bone Marrow Transplantation. .social-ris-container { ...
... bone marrow transplantation, cord-blood banking and transplantation, stem-cell harvesting and preservation, and stem-cell ... Paul Costeas, EFI Board member and founding director of the Cyprus Bone Marrow Donor Registry; Dr. Frieda Jordan; and Dr. Sevak ... the registry to date inspire hope that Armenia will become a regional center for immunogenetics and bone marrow transplantation ... Los Angeles, October 20, 2014 - For the second time since 2011, the Armenian Bone Marrow Donor Registry (ABMDR) hosted the ...
This phenomenon is used in bone marrow transplantation, when a small number of Hematopoietic stem cells reconstitute the ... In adults, haematopoiesis occurs in the red bone marrow, in the core of most bones. The red bone marrow is derived from the ... may travel in the blood from the bone marrow in one bone to another bone. If they settle in the thymus, they may develop into T ... This process indicates that, subsequent to bone marrow transplantation, symmetrical cell divisions into two daughter ...
Bone Marrow Transplantation. 32 (4): 391-8. doi:10.1038/sj.bmt.1704152. PMID 12900775. Lee E, Min HK, Oskeritzian CA, Kambe N, ... in bone marrow, to immature neutrophils". Comptes Rendus de lAcadémie des Sciences, Série III. 324 (12): 1125-32. doi:10.1016/ ... "Serum stem cell growth factor for monitoring hematopoietic recovery following stem cell transplantation". ...
"Acquired Neuromyotonia after Bone Marrow Transplantation." Neurology, vol. 54, no. 6, 2000, pp. 1390-91. ... Acquired neuromyotonia after bone marrow transplantation. Neurology, 54(6), 1390-1391. ...
... problems bone marrow transplant compatibility bone marrow transplantation in cancer treatment cancer cancer of the bone marrow ... Decision on transplantation of blood stem cells or bone marrow cancer. Decision transplant or bone marrow stem cells to treat ... Candidate for a transplant or bone marrow stem cells to treat cancer. Although stem cell transplantation or bone marrow ... if stem cell transplantation from peripheral blood or bone marrow.. *In the case of transplantation of peripheral blood stem ...
bone marrow or stem cell transplantation. *antibiotics to help prevent infection People with severely low levels of neutrophils ... Bone marrow is a soft, gelatinous tissue inside some bones. This article covers bone marrow in detail, including what happens ... these cells emerge from the bone marrow and mature in the blood instead of the bone marrow. ... Bone marrow collection involves inserting a long needle into part of the pelvis near the back of your hip. The procedure can be ...
Results were compared with two control groups: (1) 50 patients who received bone marrow depleted with CAMPATH-1M, but no ... but can be avoided by removing T lymphocytes from the donor bone marrow. However, T-cell depletion increases the risk of graft ... 459 patients reported to the International Bone Marrow Transplant Registry (IBMTR) who received nondepleted grafts and ... This study examined the use of CD52 monoclonal antibodies to eliminate T cells from both donor marrow and recipient to prevent ...
Graft Purging in Autologous Bone Marrow Transplantation: A Promise Not Quite Fulfilled. June 01, 2004 ... grafts may contribute to relapse following autologous transplantation.Graft purging involves either in vivo or ex vivo HPC ...
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J. Exp. Med. 209, 903-911 ... The gut microbiota regulates bone mass in mice. J. Bone Miner. Res. 27, 1357-1367 (2012) ...
Aim: We aimed to evaluate the risk of Q fever transmission through tissue and cell transplantation. Methods: We performed a ... the risk of Q fever transmission through tissue and cell transplantation from undiagnosed chronic Q fever cases became a ... Q fever following bone marrow transplantation. Bone Marrow Transplant. 1988;3(2):165-6. PMID: 3048481 ... 3 BISLIFE Foundation, Leiden (previously Sanquin Bone Bank, Nijmegen), The Netherlands 4 Sanquin Cord Blood Bank, Leiden, The ...
Bone marrow transplant A medical procedure in which diseased bone marrow is replaced by healthy bone marrow from a volunteer ... Learn more about bone marrow transplantation.. * Cancer A group of more than 100 different diseases that can begin almost ...
Bone marrow transplantation shows potential for treating adults with sickle cell disease Use of a lower intensity bone marrow ... transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, ...
Specialty: Graft vs host disease, bone marrow transplantation, inflammation and immunology. Bryon Johnson Laboratory. Specialty ... Specialty: Graft vs host disease, bone marrow transplantation, inflammation and immunology. Martin Hessner Laboratory. ...
Prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation ...
Clinical Pharmacy Manager - Bone Marrow Transplantation. Primary Campus: NewYork-Presbyterian Hospital / Weill Cornell Medical ...
Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 36: 123-129. ... Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 36: 123-129. ... Chagas disease in bone marrow transplantation: an approach to preemptive therapy. . Bone Marrow Transplant. 36. : 123. -. 129. ... Chagas disease in bone marrow transplantation: an approach to preemptive therapy. . Bone Marrow Transplant. 36. : 123. -. 129. ...
Gastric vascular ectasia in patients undergoing bone marrow transplantation. Marmaduke DP, Greenson JK, Cunningham I, Herderick ...
Bone Marrow Transplantation, 42, 819-827. doi: 10.1038/bmt.2008.253. Byar, K. L., Eilers, J. E., & Nuss, S. L. (2005). Quality ... Bone Marrow Transplantation, 37, 889-895. doi: 10.1038/sj.bmt.1705347. Baker, F., Curbow, B., & Wingard, J. R. (1991). Role ... Bone Marrow Transplantation, 28, 503-509. doi: 10.1038/sj.bmt.1703158. Heinonen, H., Volin, L., Uutela, A., Zevon, M., Barrick ... Setting: Bone marrow transplantation program of a National Cancer Institute-designated comprehensive cancer center in the ...
undergoing bone marrow transplantation. The treatment arm received 4 topical fluoride treatments plus Caphosol, while the ...
Experimental murine models are an essential tool in the field of bone marrow (BM) transplantation research. Therefore, numerous ... Application of the 3R principles: Vertebrae as an additional source of murine bone-marrow cells. Laboratory Animals 55(1), 43- ... Effects of analgesics on tumor growth in mouse models of prostate cancer bone metastasis. JAALAS 60(3), 341-348. ...
Bone marrow transplantation: A technique used to enhance or restore a persons immune response or supply of blood cells or to ... replace diseased or destroyed bone marrow with normally functioning bone marrow. The technique involves the removal of bone ... Leukemia: Any of several cancers of the bone marrow that prevent the normal manufacture of red and white blood cells and ... marrow from a donor and transplantation of it to a patient.. Booster immunization: A repeated vaccination against a given ...
Bone marrow MMSCs from hematopoietic stem cell donors were cultured and administered to the recipients at doses of 0.9–, ... prophylaxis following allogeneic hematopoietic cell transplantation (HSCT) were studied. This prospective clinical trial was ... The authors thank the staff of the Bone Marrow Transplantation Department for their compassionate and competent care of the ... MMSCs were derived from 25-30 mL of the stem cell donors bone marrow. For mononuclear cells, the bone marrow was mixed with an ...
Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and ... Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis ... Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled ... Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ...
VOD is a well- known complication in patients undergoing high-dose chemotherapy and bone marrow transplantation. The clinical ... Mc Donald GB: Veno-occlusive disease of the liver following marrow transplantation. Marrow Transpl Rev. 1993; 3:49-56 ...
All patients had serious underlying medical conditions, including hematologic malignancies (n = 2), bone marrow transplantation ...
Bone Marrow Transplantation. *. Cancer. *. Cancer Survivorship. *. Cervical Cancer Education. *. Chemoprevention. *. ...
Bone Marrow Transplantation. $45,396,205. Cancer. $5,927,729,104. Cancer Survivorship. $227,123,867. Cervical Cancer Education ...
Disparity for HLA in unrelated donor bone marrow transplantation (BMT) increases the risk of graft rejection and graft-versus… ... Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors ...
  • Despite antimicrobial prophylaxis, growthfactors, and new antimicrobial agents, infections are a major cause of morbidityand mortality in patients with hematologic malignancies who are receivingchemotherapy and subsequent bone marrow or stem-cell transplant. (
  • The article byWilkin and Feinberg is timely because formal recommendations on preventinginfections in stem-cell transplant recipients from the Centers for DiseaseControl and Prevention (CDC), Infectious Diseases Society of America (IDSA), andthe American Society of Blood and Marrow Transplantation (ASBMT) werepresented at the 38th IDSA annual meeting in September 2000 in New Orleans. (
  • 4-6] Marr and colleaguesrecently reported that in allogeneic bone marrow transplant recipients,fluconazole, 400 mg/d for 75 days after bone marrow transplant, was associatedwith less gut graft-vs-host disease (GVHD), persistent protection againstdisseminated candidiasis and related death, and an overall survival benefit. (
  • They included scientists and doctors from Armenia, neighboring countries, and the Armenian diaspora, as well as representatives of national bone marrow transplant centers and registries from the Caucasus, the Middle East, Europe, the United States, and elsewhere. (
  • The purpose of a stem cell transplant is to help rebuild the bone marrow, but also in the formation of healthy blood cells. (
  • Given that risks can be quite serious, the decision to get a transplant or bone marrow stem cells to treat cancer is not easy. (
  • How to transplant depends on its type: if stem cell transplantation from peripheral blood or bone marrow. (
  • Decision transplant or bone marrow stem cells to treat cancer is not easy. (
  • But when anxiety occurs, you must remember how many tens of thousands of people have been treated for cancer with stem cell transplant or bone marrow. (
  • and (2) 459 patients reported to the International Bone Marrow Transplant Registry (IBMTR) who received nondepleted grafts and conventional GVHD prophylaxis with cyclosporin A (CyA) and methotrexate (MTX). (
  • Clonogenic tumor cells contained within hematopoietic stem cell(HPC) grafts may contribute to relapse following autologous transplantation.Graft purging involves either in vivo or ex vivo HPC manipulationin order to reduce the level of tumor cell contamination.Some phase II trials suggest that patients who receive purged productsmay have a superior transplant outcome. (
  • Role retention and quality of life of bone marrow transplant survivors. (
  • Survivors of childhood leukemias and other serious hematologic diseases requiring allogeneic blood or marrow transplant (BMT) remained at elevated risk for death, even 25 years post-transplant, according to a retrospective cohort study. (
  • Our program is the only National Marrow Donor Program transplant center in northern New England and is recognized as a specialized center for unrelated donor transplants. (
  • Sanjay Agarwal is a prolific Mumbai-based freelance writer who writes on numerous topics including hair transplantation , hair transplant surgery, hair restoration & hair loss treatment , to name a few. (
  • New Delhi, May 4 : Thanks to his donor brother, a 25-year-old thalassemia patient is now living a transfusion-free life after undergoing a high-risk bone marrow transplant, doctors at BLK Super Speciality Hospital here said on Friday. (
  • But we were confident of our expertise and took up the challenge as his brother as donor made a good match and finally we were able to perform the bone barrow transplant quite successfully," Choudhary added. (
  • These were also years that led Mr. Katz to advocacy, a calling he attributes to his desire to pay forward the help he received early in his diagnosis from the late Francesca M. Thompson, MD , a renowned orthopedic surgeon, who was diagnosed with multiple myeloma in 1987 and was among the first patients with the disease to undergo an autologous bone marrow transplant. (
  • This phase II trial tests whether treosulfan, fludarabine, and rabbit antithymocyte globulin (rATG) work when given before a blood or bone marrow transplant (conditioning regimen) to cause fewer complications for patients with bone marrow failure diseases. (
  • Fungal infection is one of the most important causes of morbidity and mortality in bone marrow transplant (BMT) recipients. (
  • Non-infectious complications after bone marrow transplant: other organs toxicity II What every physician needs to know about non-infectious complications after bone marrow transplant: other organ toxicity II: Definition and incidence This section summarizes endocrine and central nervous system (CNS) complications of bone marrow transplantation. (
  • Non-infectious complications after bone marrow transplant: other organs toxicity I What every physician needs to know about complications after bone marrow transplant: organ toxicity I This section describes and discusses genitourinary system (GUS) complications of bone marrow transplantation (BMT). (
  • Non-infectious complications after bone marrow transplant: chronic graft-versus-host disease What every physician needs to know about chronic graft-versus-host disease after bone marrow transplant: Definition and incidence Chronic graft-versus-host-disease (cGVHD) is the leading cause of later non-relapse mortality and morbidity after allo-hematopoietic stem cell transplantation (HCT). (
  • Non-infectious complications after bone marrow transplant: liver complications What every physician needs to know about non-infectious complications after bone marrow transplant: liver complications: Liver complications of hematopoietic cell transplantation (HCT) are common and multi-factorial. (
  • Philips P, Wood WS, Rinaldi MG, Invasive hyalohyphomycosis caused by Scopulariopsis brevicaulis in a patient undergoing allogenic bone marrow transplant. (
  • The Tulane Bone Marrow Transplant Program is active in both autologous and allogeneic transplantation and is approved for unrelated stem cell transplantation. (
  • Blood is drawn and at a later time reinfused into that patient's blood stream in a procedure known as autologous bone marrow transplant . (
  • When stem cells are obtained from a healthy person, the procedure is allogeneic bone marrow transplant. (
  • From Boston to Bangladesh - by the bedside, in the operating room, and in the halls of the Legislature - Anselmians help people of all ages and walks of life who need a bone marrow or stem cell transplant in order to fight a life-threatening type of cancer. (
  • She was part of a team conducting autologous stem cell transplants in Bangladesh's first bone marrow transplant unit. (
  • I was able to participate in the first autologous bone marrow transplant in the country, which was a really amazing experience," says the Anselmian nursing grad, an oncology nurse practitioner specializing in leukemia and bone marrow transplants at MGH. (
  • She started as a staff nurse on a hematology/oncology/bone marrow transplant floor at Brigham & Women's Hospital, staying for four years as she studied in Simmons College's nurse practitioner program. (
  • There, she met attending physician Bimalangshu Dey, who was making his dream of opening a bone marrow transplant unit in his native country a reality. (
  • By this time he was developing a comprehensive bone marrow transplant unit there. (
  • When the nation's first bone marrow transplant was successfully completed, the nurse from Massachusetts celebrated along with the Bangladeshi nurses she had mentored. (
  • The modern bone marrow transplant unit at Dhaka Medical Center is modeled on MGH's unit on Lunder 10. (
  • VOD is a well- known complication in patients undergoing high-dose chemotherapy and bone marrow transplantation. (
  • 1 "That statistic got my attention," said Mr. Katz, who then crisscrossed the country meeting with specialists to learn more about myeloma and explore his treatment options, which were limited to chemotherapy, bone marrow transplantation, and radiation therapy. (
  • After chemotherapy, we performed stem cell transplantation from his father. (
  • Cancer-related procedures require anesthesia, such as chemotherapy, radiation treatment, and bone marrow transplantation. (
  • Medical procedures such as chemotherapy, radiation therapy, and bone marrow transplantation may be challenging to cope with if a patient experiences severe pain. (
  • In vitro, rmRetn could up regulate the CFU number of mice BM and after rmRetn was administered, the cell number of murine bone marrow was significantly increased in vivo after chemotherapy. (
  • The discovery demonstrated a new function of murine Retn and suggested that it could potentially accelerate bone marrow regeneration post chemotherapy. (
  • It was obvious that it would be meaningful to verify the new function of Retn and that it might lead directly to a potential candidate or target for relieving the bone marrow suppression by chemotherapeutic agents, which is one of the main clinical side effects of chemotherapy. (
  • Many of the side effects of chemotherapy can be traced to damage to normal cells that divide rapidly and are thus sensitive to anti-mitotic drugs: cells in the bone marrow , digestive tract and hair follicles . (
  • In the field of oncology, the department provides effective treatment of various tumors of the gastrointestinal tract, endocrine glands, female and male reproductive system, skin cancer, soft tissue and bone sarcomas, head and neck malignancies, etc. (
  • Section faculty members possess notable expertise in hematology, oncology and bone marrow transplantation. (
  • Her role was to help improve their skill set and learn the specialty of hematology oncology/bone marrow transplantation. (
  • She developed a one-year curriculum that included English training, nursing fundamentals, oncology/bone marrow knowledge, and clinical practice. (
  • We show that the place where HSCs form in the bone marrow loses osteopontin upon aging, but if you give back the missing protein to the blood-forming cells they suddenly rejuvenate and act younger," says Hartmut Geiger, PhD, study lead investigator at the Institute for Molecular Medicine and Aging Research Center at the University of Ulm, and the Division of Experimental Hematology and Cancer Biology at Cincinnati Children's. (
  • On the occasion of this important and important date we have the collaboration of Dr. Anna Sureda, head of the Clinical Hematology Service at the Institut Català d'Oncologia-Hospitalet and head of the Hematology Service at the Hospital Universitari Quiron-Dexeus in Barcelona, to answer the main questions that arise around bone marrow donation. (
  • The efficacy and the safety of the administration of multipotent mesenchymal stromal cells (MMSCs) for acute graft-versus-host disease (aGVHD) prophylaxis following allogeneic hematopoietic cell transplantation (HSCT) were studied. (
  • In bone marrow transplantation patients receiving fluconazole(Diflucan), Marr and colleagues recently reported that several'traditional' risk factors, including prolonged neutropenia, were lesssignificant predictors of candidemia than were bacteremia, CMV disease, and theadministration of quinolones. (
  • During her visit in Armenia, Dr. Kapoor gave another lecture at the Mkhitar Heratsi Yerevan State Medical University, where she spoke about recent advances in the treatment of leukemia patients and the role that ABMDR can play in helping them find compatible matches for stem cell transplantation. (
  • Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in the July 2 issue of JAMA. (
  • Gastric vascular ectasia in patients undergoing bone marrow transplantation. (
  • In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. (
  • The cohort consisted of patients (median age at transplantation, 14.6 years) who had undergone allogeneic BMT between 1974 and 2010. (
  • In severe aplastic anemia, for example, there's subgroups within the indications for bone marrow transplantations where there has been improvement and/or patients were no longer experiencing the higher mortalities or some of the chronic complications. (
  • Combination of propofol in pediatric bone marrow transplantation is indicated for patients with the maximum aerobic limit the severity of the integration of signals that identify aging or mutated cells, thus leading to the patient be managed. (
  • For patients younger than 15 years old, leukemia developed in 4 within 3 years after the liver transplantation, whereas acute lymphoblastic leukemia developed in only 1 patient. (
  • Other patients were reported in relatively early stages after liver transplantation, but our case was more than 10 years posttransplantation. (
  • Among patients younger than 16 years of age, acute myeloid leukemia (AML) developed within 4 years of liver transplantation in 3 patients, whereas acute lymphoblastic leukemia developed in only 1 patient [1]. (
  • Bone marrow transplantation is the only therapeutic option for many patients with onco-haematological diseases. (
  • The total volume of bone marrow collected depends on the weight of the patient to be transplanted, i.e. the volume is lower in pediatric patients, for example, than in adults. (
  • The authors present a pictorial essay of the high-resolution computed tomography findings in patients with pulmonary complications after bone marrow transplantation. (
  • Experimental murine models are an essential tool in the field of bone marrow (BM) transplantation research. (
  • Cannabinoids Reduce Inflammation but Inhibit Lymphocyte Recovery in Murine Models of Bone Marrow Transplantation. (
  • For this reason, an abundance of high quality and suitable murine models with impaired bone marrow was prepared in advance. (
  • Another CFU, the colony-forming unit-spleen (CFU-S), was the basis of an in vivo clonal colony formation, which depends on the ability of infused bone marrow cells to give rise to clones of maturing hematopoietic cells in the spleens of irradiated mice after 8 to 12 days. (
  • This technique has become more common than bone marrow transplants to treat cancer. (
  • Our Blood and Marrow Transplantation program offers bone marrow and blood stem cell transplants to treat lymphoma, leukemia, multiple myeloma and other tumors. (
  • bone marrow aspiration and biopsy - marrow may be removed by aspiration or a needle biopsy under local anesthesia. (
  • Finally a bone marrow aspiration and biopsy is needed to confirm the diagnosis that shows abnormal white blood cells. (
  • Currently, more than 28 million people around the world are already bone marrow donors, to which must be added the more than 650,000 cords of Umbilical Cord Blood (UCB). (
  • In Spain there are already more than 230,000 bone marrow donors and some 60,000 cords stored in public banks. (
  • It is important to emphasize that bone marrow donation is voluntary and altruistic, as is becoming a donor in a registry of unrelated donors. (
  • Since 2018, the age of an altruistic unrelated donor has been set between 18 and 40 years, this being the maximum age in cases of unrelated donors, set by the Spanish Registry of Bone Marrow Donors (REDMO). (
  • Adoptive immunotherapy with ex vivo generated cytotoxic T lymphocytes (CTLs) is applied for the treatment of leukemia relapses or viral infections after allogeneic stem cell transplantation. (
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. (
  • Dr. Leona Holmberg is an immunologist and physician who specializes in bone marrow and blood stem cell transplantation and immunotherapy. (
  • HE INCREASE in long-term survivors of living donor liver transplantations indicates that the recipients are at high risk of developing malignancies after transplantation. (
  • The cancer center at MGH is world-renowned for its expertise in bone marrow transplantation to treat blood malignancies and disorders such as Hodgkins and non-Hodgkins lymphoma, aplastic anemia, and acute leukemia. (
  • Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity after allogeneic bone marrow transplantation, but can be avoided by removing T lymphocytes from the donor bone marrow. (
  • In vertebrates, the vast majority of hematopoiesis occurs in the bone marrow and is derived from a limited number of hematopoietic stem cells that are multipotent and capable of extensive self-renewal. (
  • Hematopoietic stem cells are found in the bone marrow of adults, especially in the pelvis, femur, and sternum. (
  • In the case of transplantation of peripheral blood stem cells will be harvested and stored donor blood cells. (
  • Transplantation of peripheral blood stem cells is effective for some people, and the donation process is much simpler. (
  • In the case of transplantation of bone marrow stem cells, the process is more complicated and will be done in an operating room. (
  • During stem cell transplants , unhealthy bone marrow is replaced by healthy stem cells. (
  • These stem cells then develop into healthy marrow that produces different types of blood cells. (
  • After investigations, he was admitted for allogenic hematopoeitic stem cell transplantation as stem cells from his brother's marrow matched perfectly, the doctors said at a press conference. (
  • Red staining reveals the abundant presence of the protein osteopontin (OPN) in bone and endosteum of the marrow cavity, which is important to maintaining a healthy environment for blood-forming hematopoietic stem cells. (
  • The spectrum of non-candida fungal infections following bone marrow transplantation. (
  • The cells can be removed as liquid (to perform a smear to look at the cell morphology) or they can be removed via a core biopsy (to maintain the architecture or relationship of the cells to each other and to the bone). (
  • The body produces neutrophils in the bone marrow , and they account for 50-70% of all white blood cells in the bloodstream. (
  • This study examined the use of CD52 monoclonal antibodies to eliminate T cells from both donor marrow and recipient to prevent both GVHD and rejection. (
  • 2021. Application of the 3R principles: Vertebrae as an additional source of murine bone-marrow cells. (
  • Bone-marrow-derived multipotent mesenchymal stromal cells (MMSCs) are able to differentiate in vitro into cells of mesenchymal origin [ 9 , 10 ]. (
  • Conducting their study in mouse models, the scientists point to cells in the bone marrow called osteoblasts, which help form bone. (
  • The researchers conducted a number of experiments to test the formation and vitality of cells in and near the bone marrow microenvironment. (
  • Another experiment monitored levels of osteopontin and other proteins linked to distinct cells in bone marrow during the aging process. (
  • Scientists followed up the earlier experiments by transplanting bone marrow cells from older mice (19-21 months) into young mice (8 to 10 weeks). (
  • Transplantation into the younger animals caused cells to act in a younger more vital manner, the authors report. (
  • Normally, bone marrow cells mature into several different types of blood cells. (
  • In a needle biopsy, marrow cells (not fluid) are removed. (
  • It involves diagnosing and further management of diseases that affect the production of blood and its components, such as blood cells, hemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation. (
  • The most common indications are acute leukemias (both myeloid and lymphoblastic), myelodysplastic syndromes (malignant bone marrow diseases in which the bone marrow is unable to produce enough red blood cells, white blood cells and platelets) and in chronic myeloproliferative syndromes (hematopoietic stem cell diseases in which more white blood cells, red blood cells and platelets are produced than normal and can develop into leukemia). (
  • Apheresis is used in stem cell harvesting for circulating bone marrow cells during transplantations. (
  • Unfractionated bone tissue marrow cells had been resuspended in 0.25 ml sterile PBS and injected retro-orbitally into 10- to 13-week-old C57BL/6 mice that were lethally irradiated 115841-09-3 manufacture (10 Gy) 1 d before. (
  • Six weeks after bone tissue marrow reconstitution, we verified effective engraftment by RTPCR of Trend mRNA entirely bloodstream or FACS evaluation of EGFP+ cells and subjected mice to MCAO. (
  • Blood cancer encompasses cancers that originate in the bone marrow (organ that produces blood cells). (
  • When these abnormal white blood cells grow out of control in the bone marrow, it spills into the blood causing abnormally high circulating white blood cells which are incapable of fighting infection. (
  • In addition, too many white blood cells in the bone marrow displace other normal red blood cells and platelets and resulting in anemia and bleeding tendencies. (
  • Recently, murine Retn was found to be a possibly potential regulator of hematopoiesis in mice shown in the screening results of a set of gene chips which mapped the expression level of murine genes during regeneration of impaired bone marrow (BM) by 5-fluorouracil. (
  • In the present work, a feasible and cost-effective preparing method for rmRetn was developed and an appropriate murine model of impaired bone marrow was introduced to validate the newly discovered effect of mRetn on hematopoiesis. (
  • Setting: Bone marrow transplantation program of a National Cancer Institute-designated comprehensive cancer center in the northeastern United States. (
  • Mc Donald GB: Veno-occlusive disease of the liver following marrow transplantation. (
  • Case report of FLT3-ITD-positive AML patient 11 years after living donor liver transplantation. (
  • Case Report of FLT3-ITDePositive AML Patient 11 Years After Living Donor Liver Transplantation N. Taniai, H. Yoshida, Y. Kawano, and E. Uchida ABSTRACT With the increasing number of long-term survivors of living donor liver transplantation, the occurrence of secondary cancer is sometimes reported. (
  • This is the first case report of a patient in whom FLT3-ITDepositive acute myeloid leukemia (AML) developed more than 10 years after living donor liver transplantation for congenital biliary atresia. (
  • AML developed in a 14-year-old boy 11 years after living donor liver transplantation from his father. (
  • Herein we discuss the first case of a patient in whom FLT3einternal tandem duplication (ITD)epositive AML developed more than 10 years after a living donor liver transplantation for congenital biliary atresia and discuss the possibility of a relationship between leukemia and immunosuppressive therapy after liver transplantation. (
  • Liver Transplantation, Immediate Postoperative Care is a topic covered in the Pocket ICU Management . (
  • Anesthesia Central , (
  • In adults, haematopoiesis occurs in the red bone marrow, in the core of most bones. (
  • Currently, it is the only program in the state that performs allogeneic stem cell transplantation for adults. (
  • Eleven percent of mice which were subjected to bone tissue marrow transplantation passed away during the process. (
  • MMSCs are capable of blocking the differentiation of monocytes and bone marrow precursors into DCs [ 21 - 23 ] and inhibiting the upregulation of CD1a, CD40, CD80, CD86, and HLA-DR expression during DC maturation, which maintains DCs in an immature state [ 24 ]. (
  • The congenital dyserythropoietic anemias (CDAs) are a heterogeneous group of rare disorders characterized by anemia, the presence of erythroid hyperplasia with multinuclear erythroid precursors in the marrow, ineffective erythropoiesis and secondary iron overload. (
  • A medical procedure in which diseased bone marrow is replaced by healthy bone marrow from a volunteer donor. (
  • A procedure commonly known by the name of hair transplantation, this is an effective means that provides long lasting results. (
  • Bone marrow transplantation (BMT) is the only cure, but non-availability of a suitable HLA (human leukocyte antigen)-matched donor, inherent high risk of procedure and high cost restricts its practicality," Choudhary added. (
  • Viral infections, mainly by cytomegalovirus, are common in the second phase (up to 100 days after bone marrow transplantation). (
  • In allogeneic bone marrow transplantation, the patient's diseased hematopoietic progenitors are replaced by healthy ones from the chosen donor. (
  • The clinical use of bone marrow Cell-Based (formerly "Stem Cell") therapy is fast expanding. (
  • Bone marrow transplantation has been the treatment of choice for many hematologic diseases. (
  • When there is an infection or another source of inflammation in the body, special chemicals alert mature neutrophils, which then leave the bone marrow and travel through the bloodstream to the site in need. (
  • Besides the functions mentioned above, our lab accidentally found Retn to exert effects on bone marrow regeneration from the toxicity of chemopeutical agents. (
  • Acute myelogenous leukemia (AML) is a cancer of the blood in which too many granulocytes, a type of white blood cell, are produced in the bone marrow. (
  • Lectures and presentations in the course of the conference encompassed a broad range of topics including illnesses related to HLA antigens and the latest developments in immunogenetics, bone marrow transplantation, cord-blood banking and transplantation, stem-cell harvesting and preservation, and stem-cell applications in the treatment of blood-related illnesses. (
  • Although stem cell transplantation or bone marrow transplantation can save lives, not everyone could be candidate for this treatment. (
  • Treatment involves physical therapy to preserve bone density goes untreated and, as its cause or systemic steroids. (
  • Treatment is with colony-stimulating factors or papilloma in mouth nhs stem cell transplantation. (
  • Stem cell transplantation may be used as treatment. (
  • If you have HIV infection or had a bone marrow or kidney transplantation, Valtrex may threaten your life. (
  • This molecular image shows immunofluorescence staining in the soft spongy section of trabecular bone in the femur of a young mouse. (